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CHAPl'ER 1 
mTRClDUCTICfi 
Tryptophan's involvement in various disease entities has so 
far proven to be an excellent indicator of metabolic mechanism. If 
1 
its landmarks can be clearly established in a disease such as schizophrenia 
whose causation is still unknown, a greater understanding of the influence 
of metabolism on brain functioning miaht be expected. 
A study of tryptophan's metabolism in sChizophrenic patients 
can only be meaningful in lignt of a comprehensive consideration of 
its known metabolic activities. 
The amino acid, tryptophan, first isolated in 1901 by Hopkins 
and Cole ( 62), assumed considerable biochemical importance when it was 
shown that it could not be synthesized by l'Q8ll11118.ls but had to be supplied 
in the diet (92, 107). This essential amino acid was also found to 
be a precursor of the important vitamin, nicotinic acid (77). This 
is the only known case in which a vitamin can be produced from an 
essential amino acid. The knowledge gained from tb.e study of this 
vitamin became the basis of a cure for one of the first psychoses 
shown to have a chemical cause, pellagra. In recent years, many 
studies have pointed to bioChemical lesions as causal factors in 
sChizophrenia. Tryptophan, throuan its metabolite, serotonin, has 
been implicated in mental functioning (42, 146, 147) and there has 
been some thought that trypto!iJ.an metabolism may be impaired in 
schiz o!iJ.renia ( 99, 150). 
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Tryptophan is involved in many metabolic functions. In plants, 
such varied products as antibiotics (the pyoa.Dtibiotics, 
2-alkyl-4-hydraxyquiDoliDes) (49) and alkaloids (eserine, trigonel11De, 
harman, yohimbine, and gramine for example (14, 80) are derived from 
tryptophan and its metabolites. ID man it is important 1n the formation 
of the pyridine nucleotides which are involved in oxidation and reduction 
processes 1n the body (142). It is also involved as a chelating 
agent (22) and is probably an 1ntermediary substance 1n numerous 
metabolic pathways. However, as a precursor of serotonin, it tii8.Y be 
important as a control factor in what has been considered not only a 
pressor agent but possibly an important neurohumoral mediator. 
It is interesting to view tryptophan metabolism phylogenetically. 
Its importance in proteiD metabolism. is UDderlined by the knowledge 
that the same metabolic mechanisms appear to be used by many organisms, 
notably such dissimilar ones as Neurospora and man. It has been a 
substantial aid in the understanding of genetic activity since it is 
used as a tool in the investigation of evolutionary mutation processes 
in various types of micro-organisms and insects (9, 129). 
The study of tryptophan metabolism was indirectly begun by 
Liebig ( 83) who, 1n 1853, discovered lcyn.urenic acid in the urine 
of dogs. In addi tioo to Hopkins' and Cole 1 s isolation of tryptophan 
from casein, and Ellinger and Flamand's (32) elucidatioo of its structure, 
another important discovery in this area was that kynurenic acid was a 
metabolite of tryptophan which could be isolated from the urine of rats 
to which tryptophan had been fed (31). 
Kotake and coworkers showed that kynureniLne was an intermediary 
metabolite of tryptophan ( 76), and that it was an intermediate in the 
formation of kynurenic and anthranilic acids (75). They also discovered 
the enzyme systems involved in these conversions ( 64). 
Berg and his group (11, 19) were also very active in studying 
tryptophan metabolism.. They showed the pathways of various derivatives 
of tryptophan to kynurenic acid and did many studies on the nutritional 
aspects of tryptophan. 
Interest in tryptophan metabolism was renewed when it was 
discovered that it was a precursor of the important B vi tam.1n 1 niacin 
or nicotinic acid. 
The more recent isolation of the biologically active amine, 
serotonin (101) 1 led to more intensive studies on tryptophan metabolism 
as it was assumed from the structure of serotonin that it was likely to 
be derived from tryptophan because of the indole nucleus common to both 
these substances. Since serotonin appeared to have some cODilection 
with mental functioning (146, 147) increasing interest in tryptophan 
.metabolism was shown by investigators interested 1n the biochemical 
basis of sChizophrenia and normal mental processes. 
Normal Mstabolism. 
Tryptophan intake is mostly in the form of proteins. The 
tryptophan content of most proteins is approximately l~ with proteins 
of vegetable origin such as cereal grain much less efficient as a 
source than those of animal origin (116). Of the eiSJ,t amino acids 
essential :for the nutrition of adult man, tryptophan is required 
in smallest amounts with approximately 0.25 gm. considered as the minimal 
daily L-tryptophan requirement (~08). The amount required by most 
ID8JJJ!D8l s is in the ord r of 0.1 to 0.2'1> of the diet. 
Tryptophan is metabolized in the liver in a number of ways. 
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It is used for the formation of body protein. It is used in the synthesis 
of the liver pyridine nucleotides. The major pathway of tryptophan 
degradation is considered to be by oxidative cleavage of the indole 
ring ~eading to nicotinic acid and its derivatives via kynurenine, 
3-hyd.ro:xykynurenine and 3-hyd.roxyanthranilic acid (see Figs. l and 2). 
A number of isoptopic experiments have helped to establish this 
pathway. Heidelberger and coworkers showed that the beta carbon 
atom of the tryptophan side chain became the beta carbon atom of the 
kynurenine side chain and the C-3 atom of kynurenic acid. 'lb.ey found 
that the side chain was lost in the conversion of kynurenine to 
nicotinic acid (52). Further work from the same laboratory showed 
that carbon atom 3 of the indole nucleus became the carboxyl carbon 
atom of nicotinic acid (51). The conversion of tryptophan to kynurenine, 
kynurenic acid and xanthurenic acid in the rat and rabbit was studied 
with Nl5 .. ring-labelled tryptophan by Schayer (113). He also showed 
that labelled quinolinic acid could be isolated from rat urine after 
administration of tryptophan doubly labelled with deuterium and N15 (115). 
A number of other isotopic studies carried out by Henderson and Hankes 
(47 1 53) established intermediate steps of this pathway. 
A second pathway of tryptophan degradation is by hydroxylation 
to 5-hyd.roxytryptophan 1 5-hyd.roxytryptamine (serotonin) 1 and 
5-hyd.roxyindoleacetic acid (see Fig. 3). Udenfriend and coworkers in 
a series of papers have left no doubt that the conversion of tryptophan 
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to 5-hyd.roxyiud.oleacetic acid throusn 5-hyd.roxytryptophan and serotonin 
was a normal pathwa3 in animals and man. That tryptophan was the 
precursor of serotonin was shown by experiments in which labelled 
tryptophan was fed to rabbits and toads, followed by the isolation of 
labelled serotonin (136, 137). Furthermore, radioactive 5-hyd.roxytryptO];il.an 
was formed from labelled tryptophan by liver slices (134) demonstrating 
the pathway for serotonin biosynthesis. They have presented evidence 
that serotonin is synthesized in the animal body from 5-hydroxytryptopb.an 
and that tryptamine is not an intermediate in this process (135). 
They also administered labelled tryptophan to three patients with carcinoid 
tumors and found that they excreted labelled 5-hydroxyindoleacetic 
acid sb.owing that tryptophan is a precursor of serotonin and its 
metabolites (139). 
There are various other routes for degradation of tryptophan 
which appear to be carried out primarily by the bacterial flora of 
the gut, i.e. deamination to indolelactic acid, side chain modification 
to form indoleacetic acid either by transamination to indolepyruvic acid 
followed by oxidative cleavage or by decarboxylation to tryptamine and 
then by the action of monamine oxidase (see Fig. 4), and side chain 
cleavage to give indole, indoxyl, indoxyl sulfate and skatole. In any 
attempt at elucidation of metabolic pathways, consideration must be 
given to the various conjugates and detoxification products, sulfuric 
acid esters of phenolic compounds, methylated phenols, glycine 
conjugates of the &mines and other substances. 
Much ingested tryptophan is not accounted for by the excreted 
products of the nicotonic acid pathway, the serotonin pathway or by 
TRYPTAMIN' 
N 
H 
I CH2-y"-coou 
NU2 
TRYPTOPUAN 
N 
H 
Q 
INDOL~ACETIC ACID 
Fig . 4 . Metabolism of Tryp opr.an to lndoleq.cet · c .1\cld. 
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bacterial degradation. Dalgliesh (26) considers it unlikely that a 
pathway accounting for a large part of the tryptophan normally degraded 
still remains undiscovered . He proposed a scheme where the aromatic 
ring of tryptophan is converted via kynurenine and 3-hyd.roxyanthranilic 
acid to metabolically reactive aliphatic compounds which either are 
liberated as carbon dioxide or go into the general body metabolic 
pools of small molecules . The work of Gholson et al. (43) on the 
metabolism of D ,L- Tryptophan- c14 in the rat lends confirmation to 
Dalgliesh 1 s scheme and is contrary to the suggested degradation route 
of Sanadi and Greenberg (109) that Tryptophan-/ -cl4 was degraded 
chiefly via acetate-2-c14 in the rat. 
Abnormal ~tabolism 
Since tryptophan is involved in normal metabolism in many ways, 
it is interesting to consider the pathological conditions in which 
tryptophan and its metabolites vary, especially quantitatively, from 
the normal. In this manner insit#lt can be gained as to the mechanisms 
in which tryptophan is participant. 
Abnormal tryptophan metabolism has been observed in various 
forms of cancer (18) and some speculation that tryptophan is implicated 
as a carcinogenic agent in man has been made . This was based on the 
chemical similarities between known bladder carcinogens and the tryptophan 
metabolites normally found in urine which are aromatic amines or 
aminophenols. Some of these tryptophan metabolites such as 
3-hydroxyanthranilic acid and 3-hyd.roxykynurenine have been found 
to produce bladder cancer in mice (17). Some industrial aromatic 
amines have been found to be causative factors in bladder cancer in 
man (63 ). 
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'!he serotonin pathway, involving the hydroxylation and 
decarboxylation of tryptophan, has been found to be involved in 
carcinoid tumor conditions (82). In patients with .mal.ignant carcinoid, 
6\JI, of ingested tryptophan is converted into serotonin, whereas in 
normals only 1% is :metabolized in this manner (120). There is 
elevated urinary excretion of 5-hydroxyindole acetic acid and other 
indoles as shown by paper chromatography (25, 45, 67, 123) and 
chemical analysis (48, 121). 
Increased excretion of the tryptophan metabolites, kynurenine 
and 3-hydroxylcynurenine, has been reported in patients with leukemia ( 91). 
Febrile patients also have been reported to show disturbed 
tryptophan metabolism (27). They excrete large amounts of ;-hydroxy-
kynurenine. This is presumably formed from the endogenous tryptophan 
resulting from the breakdown of body proteins in fever. 
Numerous reports have appeared in the literature of disturbed 
tryptophan metabolism in pathological states which are associated with 
mental disorders. 
Pellagra is a disease found to be due to niacin deficiency. 
Its clinical signs include dermatitis, diarrhea, and dementia, the last 
named expressed in forms similar to some exhibited in schizophrenia (l24). 
Pellagrins do not excrete as much nicotinic acid as do normals and in 
addition show other signs of disturbed tryptophan metabolism. Tryptamine, 
not usually found in urine, has been isolated from the urine of patients 
12 
suffering from pellagra (127). It has been claimed to have hallucinogenic 
properties (33, 102). lUcotinic acid is an effective cure for this 
deficiency disease (41, 46). 
H-disease is a hereditary disease with pellagra-like skin raSh, 
temporary cerebellar ataxia and disturbances in mentality. There is 
constant renal aminoaciduria. This bizarre disease, described by 
Baron, Dent, Harris, Hart and Jepson (8) in 1956, suggests a disturbance 
of nicotinic acid utilization. Beside the clinical features found, 
laboratory tests disclose increase in the urinary excretion of indole 
compounds. In addition to an increase in indoxyl sulfate, there is an 
excess of tryptophan, indoleacetic acid and N-indoleacetylglutamine 
( 8, 66, 67). Furthermore, tryptamine, serotonin, 5-hydroxyindoleacetic 
acid and indole lactic acid · are not detectable. Baron and coworkers 
have suggested that H-disease represents a disorder of tryptophan 
metabolism wherein a metabolic block exists along the pathway from 
tryptophan to nicotinic acid. They postulate that some enzyme systems 
require nicotinic acid or nicotinamide as prosthetic groups aDd that 
these groups can only be derived from tryptophan. wbile this could 
explain the disturbances in indole metabolism and the pellagra-like 
lesions, the other signs such as aminoaciduria, cerebellar ataxia, 
and mental deficiency are still not explained. It is interesting that 
nicotinamide administration has been attempted as a farm of therapy 
but its value if any is yet to be proven. 
Porphyria is another disease with schizophrenia-like symptomatology 
in which abnormal tryptophan metabolism has been reported ( 99). There 
is elevation in the excretion of kynurenine, acetylkynurenine, 
hydroxykynurenine 1 and kynurenic and xanthurenic acids. 
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Blenylketonuria is a hereditary cond.i tion in which mental 
changes, including mental defectiveness, are a prominent feature of the 
disease. Its significance clinically lies in its disclosure of a 
metabolic defect wherein, coupled with deranged phenylalanine metabolism, 
deranged tryptol'ban metabolism leads to urinary excretion of large 
amounts of indoleacetic and indolelactic acids (5, 67, 117). 
Abnormally low levels of blood serotonin and urinary 5-hydroxyindoleacetic 
acid also have been reported (96). This disease is particularly 
interesting since it appears to be due to the inherited defect of one 
gene which manufactures an enzyme needed to convert the amino acid 
phenylalanine to tyrosine. This genetic failure, connected with 
enzyme production involving intermediary metabolism, results in 
mental deficiency. 'lhis knowledge has encouraged many workers to 
consider an enzymatic and therefore a genetic basis for other mental 
disturbances, chiefly schizophrenia. There is much interest in the 
genetic aspects indicating enzyme malfunctioning due to the work of 
KallJDADD (68) who showed a remarkable correlation between the incidence 
of schizophrenia and the degree of consanguinity in relatives of known 
sch iz opb.renic s. 
The psychotic state of schizol'brenia resembles to some degree 
such mental states as those developed under the influence of alconol, 
hashish and metal poisoning. Many people have considered the possibility 
that the organism can somehow be auto-intoxicated by some disturbed 
metabolite. The contradictory and crude evidence that accumulated 
throu~ the years was not considered sufficiently reliable for any 
acceptable generalizations. In the early work of Buscaino (20) there 
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was the suggestion that amine metabolism was involved in psychosis. The 
toxic hypothesis received indirect support when several mental illnesses 
were conclusively proven to have an organic basis. 
Various workers in the field of psychiatry have suggested the 
possibility that abnormal indole metabolites may have a causal relationship 
to schizophrenia. This consideration was based on various reports that 
indole compounds such as mescaline (71), LSD (104, 125), adrenochrome (61), 
adrenolutin (58), bufotenine (;4), tryptamine (33, 102), and dimethyl-
tryptamine (128) were psychotomimetic compoUDds (see Fig. 5). 
Hoffman, througn accidental iDhalation of LSD, noticed abnormal 
psychic effects and attempted to determine its pharmacological mode 
of activity (125). The similarities between the LSD state and some 
psychoses were immediately noted. In subsequent work with LSD, carried 
out by many investigators, connections were sougnt with serotonin, 
especially because of the common indole rings they possess. 
A whole new impetus to the search for specific metabolic faults 
in schizophrenia was given by studies of model psychosis. The structural 
similarity between the amine, mescaline, and the hormone, adrenaline, 
led Osmond and Smythies (93) and later, Hoffer, Osmond and Smythies (61) 
to suggest that oxidative alteration to adrenaline endosenously 
produced could be the toxic factor in schizophrenia. They buttressed 
their theory with reports of the psychotomimetic effects of degraded 
adrenalin (adrenochrome or adrenolutin) when administered to themselves 
and to others (58, 61). Their work added interesting connections with 
the indole theories since they recognized the chanse :from adrenalin 
to adrenochrome and adrenolutin involved the indole route. Axelrod (7) 
1' 
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however, has claimed that 3-0-methyladrenaline is the principal 
metabolite of adrenalin and has cast doubt on the adrenochrome route. 
Hoagland and coworkers at the Worcester Foundation have long 
recognized the possibility of a connection between the adrenals and 
mental disease (97). 'lhe work of the Worcester group has ranged from 
studies of brain Chemistry accompanying abnormal conditions of steroid 
balance (54-57) to investigations of the relationship of indoles to 
mental disease (37, 122). Rinkel, Hyde, Solomon, and Hoagland (105) 
were •-&mon'g' the first to propose an adrenalin metabolite, adrenoxine, 
as a possible causative factor in sChizophrenia. 
'lhe Heath and Leach group has also implicated adrenalin metabolism 
via its oxidation by sChizophrenic serum (79). While this is not 
specific to sChizophrenia since other conditions such as cancer and 
pregnancy also give this result, the observation remains of interest. 
Heath and his group have isolated a substance they call "tara.xein" 
from the copper free globulin of schizophrenic serum and have injected 
this protein fraction into normals to produce psychologically 
"schizophrenic" like states as well as abnormalities of electrical 
activity from. the septal and rostral hippocampal regions of the brain (50). 
The above work has stimulated much effort to discern alterations 
in the body fluids of schizophrenics. The kDowledge that behavioral and 
EEG changes can be induced by injection of extracts of plasma (13), 
serum. (50), or urine ( 141), provides growing evidence of an enzymatic 
alteration of metabolism in schizophrenics. The work of Wada and 
Gibson (141) strongly suggests that schizophrenic metabolism can be 
reflected in the urine in such a way as to indicate abnormality. 
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The discovery of serotonin in the brain (4, 133), its structural 
relationship to psychotomimetic drugs such as LSD (42, 147), the finding 
that serotonin-like substances Share the property of impeding ganglionic 
transmission (84), and serotonin's interaction with reserpine (ll9) 
aroused great interest and various theories were offered implicating 
serotonin malfunctioning as a possible causative factor in schizophrenia. 
The hypothesis of Woolley and Shaw (146, 147) has its base on 
the possibility that either an excess or a deficiency of the serotonin 
content of the brain can cause mental disease. Therapeutic attempts to 
utilize this theory took two forms. The first was the administration 
of serotonin's precursor, 5-hydroxytryptophan, which could cross the 
blood-brain barrier and be transformed in the brain to serotonin 
(138, 148). The second was the administration of iproniazid which, by 
inhibiting the enzyme (l5l), monoamine oxidase, responsible far the 
destruction of serotonin (15), also brougnt about an increase of the 
serotonin concentration in the brain. No straigntforward therapeutic 
results have been shown (36). 
Another form of therapy connected with serotonin is the use of 
niacin to control early schizophrenia. Hoffer and associates have 
stated in various reports (59, 60) that massive doses of nicotinamide 
are effective means of causing remission of acute schizophrenia. This 
has led to interesting observations such as that of Woolley (145) 
that nicotinamide in large amounts tranquilized animals and antagonized 
the action of serotonin on smooth muscle both in vitro and in vivo. 
Especially important was his conclusion that nicotinamide not only 
is an antagonist to serotonin but also to acetylcholine. He felt that 
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this antagonism was an indirect one and that nicotinamide was not an 
antimetabolite of serotonin. His report stresses the ability of 
nicotinamide to affect the behavior of normal animals. 
Serotonin has been classified, albeit tentatively, as a central 
neurcilum.oral agent since it was found in the brain and its concentrations 
parallel concentrations of noradrenalin in the various regions of the 
brain (23, 140). There are problems, however, in considering serotonin 
as a neurchumoral agent. For example, the mental changes resulting 
from LSD cannot be explained as a result of its antagonism to serotonin. 
The studies of Cerletti and Rothlin (21) with Brom-LSD, only one atom 
different from LSD, show that it has no psychotomimetic activity despite 
its being as powerful a serotonin antagonist as is LSD. 
Purpura's work with LSD and cortical dendritic activity (100) 
has suggested that synaptic interrelationship, as a result of dendritic 
action, might be a valid site for the neurOhumoral activity of serotonin. 
This has been based on his demonstration that dendrites are only 
synaptically excitable and he suggests that LSD activates inhib~tory 
synapses on dendrites rather than blocking excitatory synapses. This 
is a possible mode of action for LSD but the neural connection af 
serotonin to this process is in doubt since Pharmacologically active 
agents suCh as reserpine not only deplete the brain of serotonin but 
also of noradrenaline, and, in fact, the time for their metabolic 
restitution is almost identical. 
The theory that indole metabolism has some connection with 
mental illness has its basis in the hypothesis that there is an 
endogenous toxic factor in schizophrenics which either interferes with 
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normal brain cell metabolism or tbroush indirect means can alter brain 
activity. This view has been reinforced by reports 1n tne literature 
that indole derivatives cou.l.d be found 1n statistically hie9ler amounts 
1n the urine of schizophrenics than in that of normals (35, 87). 
Approximately 60 years ago, indicanuria was regarded by various 
writers as a sign of autointoxication and this was connected with 
disorders of the central nervous system. Townsend (132) reported 
instances of hish indicanuria in depressed and manic conditions and 
he tried to correlate the severity of the disturbance with elevation 
in indican output. As we know now, this relationship may well have 
been connected with pellagra psychosis as there is a basis for 
associating nicotinamide deficiency with indicanuria (106). 
Numerous reports (3) have appeared in the literature citing 
evidence for quantitative and qualitative differences between normal 
subjects and schizopnrenic patients in urine, blood, and cerebrospinal 
fluid, but most of these reports have been based on nonspecific and 
semiquantitative tests . Considerable attention has been devoted to 
indaxyl sulfate excretion in psychotic patients and normal subjects. 
Townsend (132) reported hie9l urinary levels of indoxyl sulfate in 
psychotic patients, whereas Folin (40) found normal levels. Using 
the Millon test for indoxyl sulfate, Sano (llO) indicated abnormal 
excretion in schizophrenics; on the other hand, McGeer and coworkers (88), 
using approximately the same procedure, found little difference 
between normal subjects and schizophrenic patients. Similarly, Sloje 
(118) reported no detectable difference with Millon's reagent. 
Sherwood ( ll7), using paper chromatographic procedures, reported that 
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indoleacetic acid is excreted by schizophrenic patients in much greater 
than normal amounts and that an ether-insoluble indole, tentatively 
identified as N-hydroxyindoleacetic acid, was present in high concentra-
tions 1n urine from schizophrenic patients, but absent in urine from 
normal subjects; this report has not been confirmed. The urinary 
excretion of 5-hydraxyindoleacetic acid, determined by colorimetric 
analysis, does not differ significantly in normal and schizophrenic 
subjects, but there is a greater day-to-day variability in its excretion 
by schizophrenic patients (35, 48, lll). 
The distribution of various amino acids in the fluids of the body 
indicates that tryptophan is present in the cerebrospinal fluid (131). 
It would be interesting to investigate the correlation between the 
tryptophan metabolites found in the urine a.Dd those found in the cerebro-
spinal fluid. The differences might reflect such important pathways 
of tryptophan through the blood brain barrier and possibly the 
cerebral effects postulated by Woolley could be further understood. 
Since the relationShip of tryptophan to disease processes 
involving mental signs such as schizophrenia is of importance, it is 
interesting how tryptophan metabolism can eventually affect cerebral 
activity. This field is relatively unexplored. Price and coworkers (99), 
in checking tryptophan metabolism in various diseases by paper chromato-
graphic techniques, found that there was evidence of abnormal tryptophan 
metabolism in scleroderma, in porphyria, a disease with schizophrenia-
like symptoms, as well as in schizophrenia itself. While the data on 
schizophrenia is open to question due to their establishing two different 
groups of schizophrenia to Justify their varied results, there is a 
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possibility of biochemical relationships between these diseases for 
there is in scleroderma and porphyria a disturbance of metal ion balance 
and a discussion of the effect of metal ions in schizophrenia has 
recently appeared in literature (94). It is interesting to note 
that Price and coworkers (99) found elevated zinc and copper excretion 
in porphyria as well as increased tryptophan metabolites. Once 
again the com;plexi ties of chemical interactions can be appveciated 
since scleroderma displays a urinary pattern of metabolites similar 
to porphyria and both scleroderma and porphyria respond to chelating 
~nts used therapeutically. Metal binding properties of various 
hormones such as adrenaline have been reported ( 85). 'lhis in turn 
has led to a hypothesis that the interaction of adrenaline with 
heavy metals such as iron can lead to its degradation and therefore 
may be a causal element in schizophrenia ( 94). Page ( 95) has reported 
on the similarity of porphyria and schizophrenic psychoses and Kltiver 
(70) has studied porphyrin distribution in the organism and its relation 
to behavioral disturbances. It also is interesting that Bodansky (16) 
and Duncan (29) reported on indole chromogens and porphyrin pigments 
in the urine of pellagrins. Rodnight and Mcilwain (lo6) suggest that 
where ind.icanuria has been connected with mental disorder through 
the toxic action of ind.oles, the mechanism can possibly involve the 
diversion of tryptophan metabolism from more essential routes. 
Tryptophan has metal chelating properties with essential 
minerals many of which are trace elements in the organism (22). Trace 
elements in the organism such as vitamins play an important and 
interconnecting role with tryptophan as the reciprocal relationship 
between nicotinic acid and tryptophan reveals. 
22 
The connection between tryptophan aDd enzyme synthesis is more 
direct than general.ly considered. 'lie indirect connections could lie 
in the relationship between metals and enzyme manufacture or its inhi-
bition by the binding activity of tryptophan to these metals aod 
therefore a relationship is implied involving oxidation and reduction 
activities with tryptophan as a mediator. The direct connection is 
shown by the work of Khox and Mehler (73), who found that induced 
enzyme synthesis could be clearly demonstrated in mammals. The enzyme, 
tryptophan peroxidase, which occurs in mammal ian liver, has a relatively 
low specific activity in normal animals. The specific activity was 
increased ten-fold by injecting large amounts of tryptophan. In 
further work, Khox (72) found that administration of histidine, histamine, 
and epinephrine would also increase liver tryptophan peroxidase activity 
suggest1ng that hormonal effects m1S1t have been 1nvolved in the first 
experiment. They conclude that enzymatic activity can be increased by 
a suitable inducer such as tryptophan and also nonspecifically by 
the activation of the pituitary-adrenal system. 
The ubiquity of tryptophan in metabolism makes it difficult to 
folloW all of its pathways as well as delineate all the mechanisms in 
which it participates. Tryptophan is known to be incorporated in many 
proteins. It is of interest to consider how it is 'Oound in serum. 
McMene.:acy- and Oncley (90) have shown that serum. albu.m.in is the only 
plasma. proteiD 'Which bitlds L-tryptophan appreciably and does so in a 
hiS1ly stereospecific maDner. Of importance to this area of investigation 
is the elucidation of the indole ring as a strong point of attachment 
at the binding site. 
In the tortuously convoluted area of biochemistry and its 
relationship to schizophrenia, the problem is not how tryptophan 
might be implicated in mental illness but how it could possibly not 
be involved. We have seen that vitamins, especially those of the B2 
group, act by catalyzing the use of various amino acids. The fiel.d 
of vitamins is one which is still far from clear even in nor.mal 
metabolism. Tryptophan is impl.icated in nitrogen balance and nitrogen 
balance has been shown by GJessing (44) to be a factor in schizophrenia. 
It was necessary to study tryptophan .metabolism in animals 
and in man to get some clues -to a more concrete understanding of how 
it is involved in schizophrenia and in normal physiology. To do so 
the urinary metabolites of radioactive, c14~l.abelled tryptophan were 
studied in rats and in man by a combination of paper chromatographic 
and radioautographic techniques applied to the urinary samples. It 
was felt that the radioautographic technique added extra depth and 
provided opportunities for more specific understanding of molecular 
changes in tryptophan degradation. Rats were utilized to perfect 
the methods as well as to obtain indications as to possible tryptophan 
metabolism in man. 
Of the qualitative and semi-quantitative methods of investigation 
of urinary substances, the two-dimensional paper chromatographic 
method of Dent (28) appears to be the most satisfactory. It is possible 
by this method to separate and characterize individual components of 
a compl.ex miXture, such as may be found in urine, by two Rr values and 
also by fluorescence and/or color developed by reaction with a wide 
variety of re~nts. The chromatographic analysis of urine may be 
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accomplished by spotting whole urine directly on paper, or by spotting 
after extraction procedures of varying complexity or by preliminary 
selective adsorption followed by elution. Jepson (67), utilizing 
the two-dimensional technique, applied whole urine to the paper, and 
after reaction with Ehrlich's reagent, found that carcinoid tumor 
patients gave a strong reaction far 5-hydroxyindoleacetic acid, a 
sli~t reaction far its sulfate ester, and traces of other unidentified 
indoles; similarly, urine from phenylketonuric patients reacted strongly 
far indoleacetic acid and indolelactic acid. Dalgliesh (25) also 
employed the two-dimensional technique, but spotted a concentrate 
of the phenol eluate of a deactivated charcoal adsorbate of urine; 
Ehrlich's reagent indicated the presence of considerable amounts of 
both serotonin and 5-hydroxytryptophan, as well as 5-hydroxyindoleacetic 
acid. 
Riegelhaupt (103), using Jepson's technique, reported that an 
unknown indole, characterized by a quickly fading blue spot of Rr 0.63 
in isopropanol-ammonia and 0.47 in n-butanol-acetic acid, was found in 
the majority of schizophrenic urines, but was absent in urine from 
healthy adults. ~Geer and coworkers (86) chromatographed pooled 
urines from five groups : a} normal subjects, b) nonschizophrenic 
mental patients, c) acute schizophrenic patients, d) chronic schizo-
phrenic patients, and e) phenylketonuria patients. The urines were 
treated with carbon, eluted with phenol-saturated water and concentrated 
under vacuum, a procedure similar to that used by Dalgliesh. The Rf 
values for Ehrlich-positive spots showed that none were found in urines 
from normal subjects and thirteen spots appeared in the schizophrenic 
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samples. Feldstein, Dibner, and Hoagland (35), in a paper chromatographic 
study of the excretion of urinary indoles in normal subjects and chronic 
schizophrenic patients, found that more indoles seemed to be excreted by 
schizophrenics than by the normal controls, but as the chromatographic 
data are semiquantitative at best, the conclusions drawn are tentative. 
Feldstein, Hoagland and Freeman (37), in a later investigation, 
concluded that there do not appear to be differences in urinary indole 
metabolism between normal persons and sChizophrenic patients and that 
apparent differences may be explained by the fact that a large enough 
population had not been studied, and that the differences that sometimes 
appear may be due to lack of dietary controls and other factors associated 
with institutionalization. 
Other pertinent studies in the area of urinary indole excretion 
in normal subjects and schizophrenic patfents have been carried out 
by Acheson (1), Armstrong (6), Curzon (24), and Young (149). 
Early work using radioautographic methods was mostly confined 
to the study of radioactive substances in histological preparat i ons (39). 
Fink, Dent, and Fink (38) were the first to combine radioautography 
with two-dimensional paper chromatography in the study of radioactive 
iodine .metabolism in rats. Calvin and his group have very successfully 
used this combination of techniques in their studies of photosynthetic 
mechanisms (10). Tomisek et al. (130) have reported on their chromatogram-
autoradiogram procedure in studying purine metabolism in bacteria. 
Leifer et al. (81) have applied it to the study of nicotinic acid 
metabolism in rats. Two recent studies have appeared using these 
methods in the study of serotonin metabolism in rats and in rabbits (89, 69). 
To our knowledge, the application of this technique to the study of 
human metabolism has not been made previously. 
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CHAPI'ER II 
STUDIES WITH EXPERIMENTAL ANIMALS 
Procedure 
Animals 
Ei~t male albino rats (a Sprague-Dawley strain obtained from 
the Charles River Breeding Lab'oratories, Cambridge, Mass.), weighing 
between 190 SDd 210 grams were used for these experiments. 
Methods of Radioactive Administration 
and Urine Collection 
Preparation and Administration of Radioactive Tryptopnan 
D, L-Tryptophan-} -cl4 was obtained from Nuclear-Chi cago, Chicago, 
Illinois. The specific activity of the tryptophan administered to 
Rats 1-4 was 22.7 )lC/mg. and of that administered to Rats 5-8 was 
16.7 ;,Lc/mg. 
The radioactive tryptophan was dissolved in physiological saline 
and a 2.0 ml. aliquot containing 15 to 25 ;« c (1.1 to 1.2 mg.) of 
radioactivity was administered intraperitoneally to the rats. 
Urine Collection 
Rats were kept individually in metabolism cages1 and supplied 
with ground food and water. The cages were specially constructed so 
that no food or feces could drop into the urine. The urines were 
collected in graduated tubes at 24 hour intervals for a period of seven 
1 A62 Rat Metabolism. Cage, Acme Metal Products Co., Chicago 19, 
Illinois. 
days and were refrigerated until ready for use. The urine volumes 
raDged from 3 to 21 ml. for a 24 hour period. 
Extraction Proeedures 
Solvents 
Hexane: redistilled hexane was used. 
Isopropyl acetate: washed three times with distilled water. 
Isopropyl ether: washed three times with ferrous sulfate and then 
with distilled water to remove peroxides. 
n-Butanol: redistilled butanol was used. 
Rats 1- 4 
The first 24 hour urines of rats 1- 4 were treated separately; 
the urine was diluted to 15.0 ml. with distilled water, acidified 
to pH 1 with caccentrated hydrochloric acid, saturated with salt, 
shaken mechanically for five minutes with an equal volume of hexane, 
centrifuged, and the hexane extract decanted. Three hexane extracts 
were made. These were followed serially by three isopropyl ether 
extracts, three isopropyl acetate extracts, and finally, after 
adjusting the pH to 12, by three isopropyl acetate extracts. The 
extracts were counted (see Table '4, p. 44· ) and chroma.tographed on 
paper (see Table ~' p. 41). 
Rats 5-8 
The first 24 hour urines of rats 5-8 were pooled. Two 15 m.l. 
aliquots were set up for extraction. They were acidified to pH 1 
with concentrated hydrochloric acid, saturated with salt, shaken 
mechanically for five minutes with isopropyl ether, centrifuged for 
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five minutes, then filtered throu€!P glass wool to remove materials 
causing a gel. The material was then extracted successively three 
times with isopropyl ether, three times with isopropyl acetate and 
three times with butanol to remove the remaining radioactivity. The 
extracts were counted (see Table 4 and Fig. 8, p. 45) aDd chromate-
graphed on paper (see Table 5 ) . 
Radioactive Counting Methods 
Planchet Preparation 
Ten microliter aliquots of the urine were planChetted in 
triplicate and counted on an automatic gas flow counter (Nuclear 
Chicago D47 Gas Flow Counter with "Micromil" window and automatic 
sample Changer). All counts were corrected to the same efficiency. 
It was not necessary to correct for self-absorption as the material 
was counted at zero thickness. 
Scintillation Counting 
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Some urine samples and all the extracts were counted in a 
Packard Liquid Scintillation Spectrometer, Model 314X. Three 0.10 ml. 
aliquots were removed from each urine sample or extract to be counted. 
To these were added 4.0 ml. of absolute ethanol and 10.0 ml. of 
scintillation solution (scintillation grade toluene containing 0.4~ 
of 2,5-dipb.enyloxazole (DPO) and 0. 01~ of 1,4 bis-2-(5-phenyloxazolyl)-
benzene (POPOP). All samples were counted in triplicate using 5-dram 
glass vials of l ·ow x.4o content2. All radioactive counts were corrected 
~eaton Glass Co., Milleville, N.J. 
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for quenching by tne addition of an internal standard c14-tryptophan 
solution. 
Paper Chromatographic Techniques 
Solvent Systems 
First: Isopropanol-ammonia:-water (20:1:2): Isopropanol, 800 ml.., 
concentrated ammonia, 40 ml.., distilled water, 80 .ml. 
Second: Butanol-acetic acid-water (12:3:5): n-Butanol, 600 ml.., glacial 
acetic acid, 150 ml., distilled water, 250 ml.. 
Location Reas!nts 
Ehrlich's reagent: 1~ p-dimethylaminobenzaldehyde in 101> hydrochloric 
acid-ethanol. 
Dras!nd.Orf' s Reagent Spr~: 
Preparation of Stock Solution of Potassium Bismuth Iodide 
To an erlenmeyer flask add: 
1. 2.5 grams of bismuth subnitrate 
2. 10 ml. of 401> potassium iodide (4 grams of Kl in 10 ml.. water) 
3. 5 ml.. of glacial acetic acid 
4. 20 ml.. of distilled water 
5· Refrigerate overnight and then filter 
Preparation of Spray 
Just before using, mix 5 ml.. of stock potassium bismuth iodide 
solution, 10 ml.. of glacial acetic acid and 30 ml.. of distilled water. 
Naphthanil Diazo Blue B Spray: 
0.1 grams of Naphthanil Diazo Blue B (tetradiazotized di-o-anisidine) 
was dissolved in 30 ml. of distilled water and 20 ml.. borax buffer, pH 9.2, 
added immediately before use. (Borax buffer: Dissolve 33.2 grams of 
sodium. borate • 10 ~0 in 1 liter of distilled water). 
Gibbs Reagent (DQC): 
2,6 dichloroquinone chloroimide, 0.2~ in ethanol. 
Udenfriend Rea,sent: 
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1. 1-Nitroso-2-naphthol: Wei~· out 1.0 grams of 1-nitroso-2-naph.thol 
and dissolve in 1 liter of absolute alcOhol; filter. 
To 50 ml. of the 1-ni troso-2-naph thol solution, add 50 ml.. of absolute 
ethanol. 
2. Nitrous acid: Weigh out 0.5 grams of sodium nitrite and dissolve 
in 20 ml.. of distilled water. 
To 2 ml.. of the sodium nitrite, add 48 ml.. of 2N hydrochloric acid. 
Prepare fresh daily. 
Spotting and Cochromatography 
Two-dimensional paper chromatograms were prepared on 10 by 12 
inch Whatman No. 1 chromatographic paper. The material was spotted in 
the lower right hand corner of the paper. The spot was dried under a 
stream of nitrogen. The simultaneous chromatographing of synthetic 
substances with the material being studied, i.e. urine, extract, etc., 
was carried out in order to help establish the identity of probable 
metabolites. 
Neat Urines (untreated urines): 150 ~· of urine were spotted 
on the papers and chromatography was carried out in the manner described. 
Extracts, Rats 1-4: Paper chromatograms were made of each 
extract, 1 ml.. of the extract being spotted. The location reagents 
used were: Ehrlich's, Gibb's, NaphthanU Diazo Blue B, and Ud.entriend's. 
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Extracts, Rats 5-8: Paper chromatograms were .made of' each 
extract and cochromatography was carried out with possible metabolites 
such as indoleacetic acid, indolecarbaxylic acid, indoleacetylglycine, 
kynurenic acid and xanthurenic acid. Ehrlich's reagent was used to 
visualize all these except that kynurenic acid required Dr~ndorf''s 
re~nt and xanthurenic acid required NaphthanU Diazo Blue B f'or 
their visualization. 
Develgement of' Papers 
The asceoding technique of' Williams and Kirby (144) was used. 
The papers were clipped into cylindrical form and placed in a glass 
chromatography tank, 24 inches hif#:l by l2 inches in diameter, the bottom 
of' which was fitted with a circular stainless steel plate with a 
buUt-in leveling device. The first solvent system used was isopropanol-
ammonia-water kept at a constant temperature of' 3000. After an 
overni£jlt run (16 hours), the papers were removed, air dried, rotated 
throusb 90° and again stapled into cylindrical form. The papers were 
then placed in a tank containing n-butanol-acetic acid-water at 30°0. 
After 6 hours, they were removed, dried, and sprayed with Ehrlich' s 
reagent to bring out the indole spots. Other sprays were used such as 
Udenf'riend's re~nt f'or the detection of' 5-hydraxyindoles and 
Naphthanil Diazo Blue B f'or the visualization of' 5-hydroxyindoles aod 
phenols. 
R£ and Color Determination 
When dry, the papers were placed on an opal glass, intensely illuminated 
from the rear (by fluorescent light) and the spots were circled. The Rf' 
values and the colors of' the spots were recorded. The papers were 
re-examined after 24 hours to note color Changes and fading. 
The system of color naming that is most frequently used, i.e. 
red-purple, blue-purple, etc. was found to be too subjective and 
otherwise unsatisfactory. Therefore, a method that would be readily 
reproducible was chosen, viz. , the Spectrum and Color Charts found 
in Webster's New International Dictionary, 2nd Edition, which is 
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available in any library. Their system of using numbers to represent 
the colors was found very rapid and convenient. (See Color Charts 
in Appendix, p. 109-111). 
Radioautographic Techniques 
In order to determine visually which metabolites of tryptophan 
were radioactive, radioautograms on x-ray film were made of the 
chromatograms. The jJ rays of the cl4 in the chromatographic spots 
eXposed the x-ray film and produced darkened areas on the film 
corresponding to those chromatographic spots which were radioactive. 
Radioautograms were prepared of the chromatograms of the 5 hour, 
24 hour, 48 hour and up to the 168tb. hour rat urine and of each type 
of urinary extract. 
The paper chromatograms were "sandwiched" between two 10 by 12 
inch Sheets of KOdak No-Screen X-ray film and placed in a Kodak X-ray 
Exposure Holder and a press to prevent lig>.t leakage. The use of two 
films enabled us to develop one film early while allowing the other to 
be exposed to the chromatogram for a longer period of time. The films 
were developed after eXposure of from three weeks to four months3. 
3we wish to thank Mrs. Mary Ryder of the X-ray Department of 
the Worcester State Hospital for a eveloping many of the films for us. 
By preparing a series of papers with a known amount of radioactivity 
and exposing these for three months, we found that we were able to detect 
as low as 33 counts/min. as a very faint spot. 
The Rf values were recorded and compared with the Rf values of 
the spots which appeared on the Ehrlich-sprayed Chromatograms. 
Results 
Recovery of Administered Radioactivity 
The cumulative percent recovery of administered radioactivity 
after D ,L-Tryptophan-} -c14 was intraperitoneally administered to eight 
rats was 4. 4% with a range of from 3 .1 to 6. CYf, (see Table 1). The 
percent recovery of radioactivity in time after tryptophan administration 
is given for each of the eight rats in the appendix (see Tables 16-22). 
It can be seen by examination of these tables and of Fig. 6 that 
of the urinary radioactivity recovered, half was recovered in the first 
14 hours, i.e. 14 hours is the biological half' life of the radioactive 
tryptophan in rats (see Table 2). Urines were collected and counted for 
seven days after tryptophan administration. Seventy-two per cent of 
the urinary activity was found in the first 24 hours and 83~ of it was 
out in 48 hours (see Table 24, p. 93 in Appendix). After 168 hours 
only small amounts of radioactivity (less than 0.2~) were excreted. 
Identification of Radioactive Metabolites 
Examination of the radioautograms of the neat urines after an 
exposure of two to three months Showed the presence of some forty 
radioactive spots (see Map of Spots, Fig. 7). Table 3 presents the 
distribution of radioactive spots in successive urine collections 
TABLE 1 
BECOVE.RY OF RADIOACTIVITY FROM RAT URINE FOLLOWING 
INTRAPERITONEAL AD~USTRATION OF D 1 L:-TRYPrOPHAN 
_fi -c (15-25 Ji-c) 
Rat No. 
1 
2 
3 
5 
6 
7 
8 
Total Percent Recovery 
of Administered Radio-
activity 
3·7 
5·7 
6.0 
5.0 
3.5 
3.1 
4.4 
Mean 4.4 
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TABLE 2 
BIOLOGICAL HALF-Lll'E OF D 1L-TRYPrOPHANj& -c14 IN RATS 
Rat No. Biological Half-Life 
(hours) 
l l2 
2 8 
3 l2 
4 18 
5 14 
6 14 
1 15 
8 16 
Mean 13.6 
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TABLE 3 
DISTRIBllriON OF RADIOACTIVE SPOI'S lN SUCCESSIVE URINE COLIE!~IONS 
FOLLOWING INTRAPERITONEAL ADMINISTRATION OF D ,L-TRYPrOPHAN-}' ..C TO RATS 
Radio- Ra.dioautograpnic Spots in Ra.dioautograms 
auto- R 's Intensi tya 1n Timed Urine Collections Correspondingb Tentative 
grapn- Isopro-f Butanol- 0- 4.5- 24- 48- 72- 96- 120- 144- Ehrlich Identifi-
ic map panol Acetic 4.5 24 48 72 96 120 144 168 Color No. cation 
spot no. ~~o~~~ Acid hrs. hrs. hrs. hrs. hrs. hrs. hrs. hrs. 
---------- --
- -
1 .03 .15 E 
2 .03 .21 D 
3 .03 .26 D 
4 .03 .40 D E 
5 .03 .47 A F F 122 
6 .03 ·51 A c E E E E E E light 79 Xanthur-(late) enic Acid 
7 .03 .65 F F 
8 .10 
· 33 D E F 
9 .16 .29 B c E E E E F F 119 (late) 
10 .17 ·93 E F 95 
11 .17 .80 D E F 87 5-Bydro:xy-
indo1eacet-
ic Acid \)I \0 
TABLE 3 continued 
Radio- Radioautographic Spots 1n Radioautograms 
auto- Rt' s Intensi tya r1fi Timed Urine Collections Correspond.ingb Tentative 
graph- Isopro- Butanol- 0- 4.5- 24- 48- 72- 96- 120- 144- Ehrlich Identifi-
ic map panol Acetic 4.5 24 48 72 96 120 144 168 Color No. cation 
spot n~. ~~OJ:lia Acid hrs. hrs. ~ ~ ~ ~ ~ ~ 
12 .17 .68 C D 
13 .17 ·57 B E F 
14 .21 .45 B D 
15 • 23 • 52 B D 94 Tryptophan 
16 .30 .35 B C E F F F F F 84 (late) a 5-Hydrox-
yind.olec 
17 .36 .94 D D E F 98 Indolecar-
18 .36 .84 D D F 90 
19 .36 .72 B C 
20 .;6 .60 B E F F 
21 .41 .33 E F 
bo:xylic 
Acid 
22 .50 .94 B C D D D D D D 90, 94, 96 Indoleacet-
ic Acid 
23 • 50 • 71 C E E +:' 0 
TABLE 3 continued 
Radio- Radioautographic Spots in Radioautograms 
auto- &'s Intensitya 1il Timed Urine Collections Correspondingb Tentative 
graph- Isopro- Butanol- 0- 4.5- 24- 48- 72- 96- 120- 144- Ehrlich Identifi-
ic map pano1 Acetic 4.5 24 48 72 96 120 144 168 Color No. cation 
spot no. Ammonia Acid hrs. hrs. hrs. hrs. hrs. hrs. hrs. hrs. 
24 .50 .66 A C E E E E E E Kynurenic 
Acid 
25 .52 .84 A B B B C D D D 92 89 Indo1eacet-
y1 Glycine 
26 .52 .40 E 
27 .54 .61 E 
28 • 55 • 57 137 Urea 
29 .63 .90 F F 95 Acety1tryp-
tophan 
30 .66 .94 C C F F F F 106 Unknown 
Indo1ec 
31 .66 •77 D 
32 .66 .47 E E F F F F 
33 • 72 .60 D E E F F F F 85 6-Hydroxy-
skato1e 
Sulfate 
34 • 72 • 71 D D E ~ 
..... 
TABLE 3 continued 
Radio- Radioautographic Spots in Radioautograms 
auto- !f's Intensit 1il Timed Urine Collections Correspondingb Tentative 
graph- Isopro- Butanol- 0- ·5- 2 - - 72- - 120- 1 - Ehrlich Identifi-
ic map panol Acetic 4.5 24 48 72 96 120 144 168 Co1or No. cation 
spo~_no. A~ia Acid hrs. hrs. hrs. hrs. hrs. hrs. hrs. hrs. 
- -
35 ·75 .78 D D 
36 .80 ·93 D F 106 
37 .82 .82 E E 
38 .84 .89 c F 
39 .96 ·75 B D E 
40 .96 
·55 E E 97 
aA designates radioautographic spots of hi~est intensity, F, spots of lowest intensity. 
bsee Tab1e 37, p. 108 and Co1or Charts, pp. 109-111 in Appendix. 
cThis appear\ to be present in extracts of human urine following administration of 
D ,L-Tryptopnan-ft -cl . 
+=" 
1\) 
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following the intraperitoneal administration of D,L-Tryptophan-~ -cl4 
to rats. The data support the radioactive measurements Showing that 
the radioactivity recovered falls off sharply after the first 24 hours. 
By Rf, Ehrlich color and cochromatography with synthetic compounds, 
eight of the radioactive metabolites derived from the administered trypto-
phan were tentatively identified plus the labelled tryptophan itself. 
Referring to the composite map of spots (Fig. 7), these labelled metabolites 
are: acetyltryptophan (#29), 5-liydroxyindoleacetic acid (#11), 6-hydroxy-
skatole sulfate (#33), indoleacetic acid (#22), indoleacetylglycine (#25 ), 
indolecarboxylic acid (#17) , kynurenic acid (#24), and xanthurenic acid (#6). 
The tryptophan is #15 . (For comparison, see Table 36, p. 105 in appendix 
for Rf's of synthetic metabolites.) 
There were also a 5-hydroxyindole (#16) and an indole (#30) 
which correspond to radioactive spots found in extracts of human urine 
following the administration of radioactive tryptophan. 
In order to obtain further information as to the nature of the 
radioactive metabolites, the various extracts of the rat urines were 
studied. 
The radioactivity in the various extracts was measured by 
scintillation counting. Table 4 presents the percentage distribution 
of radioactivity in these extracts . Fig. 8 is a schematic representation 
of these data for rats 5-8. It can be seen that hexane was a very 
inefficient extraction solvent, extracting less than li of the 
radioactivity, and was therefore discarded in the second series of rats. 
Basic isopropyl acetate was also a very poor extractor of the metabolites 
concerned, extracting less than 2~ of the radioactivity, and was also 
TABLE 4 
DISTRIBtJriOO OF RADIOACTIVITY m SUCCESSIVE SOL VENT 
EXTRACTIONS OF URINE COLLECTED FOR 24 HOURS FOLLOWING
14 INTRAPERITONEAL ADMINISTRATION OF D ,L-TRYPrOPHAN-J -C 
44 
Percenta~ Distribution of Radioactivitl 
Extract Rat 1 Rat 2 Rat 3 Rat 4 Rats ~-aa 
Acidic Urine (pH 1) 
Hexane 0.83~ 0.5~ o. 7CJ1, 0.44~ 
Isopropyl Ether 20.8 16.1 17·9 19.8 12.3 
Isopropyl Acetate 25.8 18.8 20.1 25.2 17.8 
n-Butanol 55·5 
Basic Urine (pH 12) 
Isopropyl Acetate 1.85 1.06 1.34 1.07 
Residual Urine 73·7 50.4 60.9 56.5 13.7 
Total Recover~ of 
Radioactivitl 123.0 87.0 100.8 103.0 99.3 
~e 24 hour urine collections from rats 5 through 8 were pooled 
prior to extraction. 
bnue to the large amount of salt in the residual urine, counting 
was not more accurate than ± 25~· 
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dropped. Isopropyl ether (12-21~) and isopropyl acetate (18-26i) were 
both effective and n-Butanol was most efficient of all, extracting 
almost all of the remaining radioactivity (56i). 
In each instance, the first extract of the series was the most 
efficient. Table 5 snows the distribution of radioactive metabolites 
in the various types of extracts. For example, xanthurenic acid was 
weakly extracted by isopropyl ether, .much more efficiently extracted 
by the isopropyl acetate and a small amount remained to be extracted 
into butanol; the major portion of the indolecarboxylic acid was 
removed by the isopropyl ether with a small amount remaining to be 
extracted in the isopropyl acetate and none remaining to be extracted 
into butanol. 
Radio-
autographic 
map spot no. 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
TABLE 5 
DISTRIBtJriW Q'F RADIOACTIVE SPCY!'S m SU':CESSIVE SOLVENT EXTRACTIONS OF RAT14 URINE COLLECTED AFrER INTRAmRITONEAL ADMINISTRATION OF D1 L-TRYPl'OPHAN-/ -C 
Intensi tya of Spots in 
Radioautograms of Extracts 
Radioautographic Rf' s Isopropyl Isopropyl n-Butanol Tentative 
Isopropanol- Butanol Ether Extracts Acetate Extracts Extracts Identification 
Ammonia Acetic Acid 1st~ 3rd 1st 2nd 3rd 1st 2Dd 3rd 
.03 .15 E F 
.03 .21 E 
.03 .26 E F F 
.03 .40 D F 
.03 .47 c 
.03 ·51 F F F c c c c F Xanthurenic Acid 
.03 .65 
.10 
·33 
.16 .29 
.17 ·93 F 
.17 .80 
.17 .68 F 
~ 
-.;J 
TABLE 5 continued 
Intensitya of Spots in 
Radioautograms of Extracts 
Radio- Radioautographic Rr's Isopropyl Isopropyl n-Butanol Tentative 
autographic Isopropanol- Butanol Ether Extracts Acetate Extracts Extracts Identification 
map spot no. Ammonia Acetic Acid ~~3rd 1st 2nd 3rd 1st~ 3rd 
13 .17 
·57 F F F 
14 .21 .45 
15 .23 .52 
16 .30 .35 E F a 5-HYdraxyindole 
17 .36 .94 D F Indolecarbaxylic Acid 
18 .36 .84 
19 .36 ·72 E E F F F F D 
20 .36 .60 E 
21 .41 .33 F 
22 
·50 .94 c F E Indoleacetic Acid 
23 ·50 ·71 E F E 
24 ·50 .66 D D D B E Kynurenic Acid 
25 ·52 .84 c c c B c F Indoleacetyl glycine 
.f::'" 
26 .52 .40 
0> 
TABLE 5 continued 
Intensity& of Spots in 
Radioautograms of Extracts 
Radio- RadioautograPhic Rf's Isopropyl Isopropyl n-Butanol Tentative 
autographic Isopropanol- Butanol Ether Extracts Acetate Extracts Extracts Identification 
map sJ)ot no. Ammonia Acetic Acid ~2nd 3rd 1st~ 3rd ~~3rd 
27 .54 .61 
28 
·55 ·57 
29 .63 .90 F F Acetyl tryptophan 
30 .66 .94 F Unknown Indole 
31 .66 ·11 F 
32 .66 .47 
33 ·71 .60 E 6-Hydroxyskatol.e 
sulfate 
34 .72 .71 F F E 
35 ·75 ·78 E 
36 .80 ·93 F F F F 
37 .82 .82 E 
38 .84 .89 D 
39 .96 ·75 F F E ~ \0 
Radio-
autographic 
ma;e s_;pot no. 
40 
Radioautographic Rf's 
Isopropano1- Butano1 
Ammonia Acetic Acid 
.96 
·55 
TABLE 5 continued 
Isopropy1 
Ether Extracts 
~~3rd 
Intensity& of Spots in 
Radioautograms of Extracts 
Isopropy1 n-Butano1 
Acetate Extracts Extracts 
1st 2nd 3rd 1st ~ 3rd 
F 
Tentative 
Identification 
a 
'A designates radioautographic spots of hi@J.est intensity, F, spots of 1owest intensity. 
\JI 
0 
CHAP!'ER III 
STUDIES WITH MAN 
Procedure 
Subjects 
The subjects were nine male chronic sChizophrenic patients 
at Medfield State Hospital, Medfield, Mass. They ranged in age 
from. 35 to 66 years with an average age of 46. They had been 
hospitalized from 13 to 22 years with an average hospitalization 
of 17 years. 
The normal subject was a 34 year old attendant at Medfield 
State Hospital. Since only one normal subject was used, it is, of 
course, impossible to make any comparisons between schizophrenic 
patients and normal subjects. 
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Table 6 summarizes the clinical material concerning the subjects. 
Methods of Radioactive Administration 
and Urine Collection 
Preparation and Administration of Radioactive TEypt?phan 
D,L-Tryptophan-~-cl4 with a specific activity of 9.1 ~/mg. 
was obtained from Nuclear Chicago, Chicago, Illinois. Permission for 
the administration of cl4_tryptopb.an to humans was granted by the 
u. s. Atomic Energy Commission (License No. 20-1225-2, Amendment 
No. 4). 
It was decided to administer the tryptophan in two ways: 
orally, as this is the normal route of tryptophan intake, and 
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TABLE 6 
CLINICAL DATA ON SUBJECTS RECEIVING D ,L-TRYPI'OPHAN-_1-cl4 
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 
Age 66 35 42 37 54 (years) 
Wei~t 130 160 
(lbs.) 132 124 180 
Hospitalization 13 14 17 16 19 (years) 
Diagnosis Chronic Dementia Dementia Dementia Dementia 
sch.lzo- praecox, praecox, praecox, praecox, 
phrenia other catatonic catatonic paranoid 
with de- types (Lobotomy, 
pressive (suicidal) 1951) 
features (Deceased 
'59 gall-
bladder) 
Patient 6 Patient 7 Patient 8 Patient 9 Normal Control 
Age 53 42 43 45 34 (years) 
Wei~t 172 140 160 158 162 
(lbs.) 
Hospitalization 20 13 21 22 None 
(years) 
Diagnosis Dementia Dementia Schizo- Dementia Hospital 
praecox, praecox, phrenic praecox, attendant 
catatonic mixed reaction, paranoid with no 
(LobotOJcy type chronic history of 
1948) undiffer- mental dis-
entia ted turbance 
(TB) 
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intravenously to study the actual metabolism in the tissues where it 
is incorporated into the body proteins. 
Oral Administration: Five. microcuries of the radioactive tryptophan 
(about 0.5 mg.) was dissolved in O.l N sodium bicarbonate and adminis-
tered in orange Juice. 
One patient was administered 5 miorocuries of radio-active 
tryptophan only (patient 5). Another patient was administered the 
radioactive material together with a. small load (500 mg.) 1 still 
within physiological limits (patient 6). Three patients were pretreated 
for from 2 to 6 weeks with non-radioactive L-tryptopban, 2 grams per 
day, and then were a.dministered a. 5 gram load of non-radioactive 
L-tryptopha.n suspended in raspberry syrup and miXed with orange juice 
along with the radioactive material (patients 7, 8, 9). (See Table 
11 P• 60.) 
Intravenous injection: Radioactive tryptophan (about 0.5 mg.) was 
dissolved in physiological saline or in O.l N sodium bicarbonate and 
was sterilized by filtration througn a. bacteriological filter4 and 
collected into a. sterile, sealed, serum bottle. Approximately 2.5 ml. 
of the solution, containing 5 microcuries of the radioactive tryptophan, 
was administered intravenously (in the antecubital vein) to patients l-4 
by Dr. Harry Freeman at Medfield State Hospital • (See Table 8, 
p. 61.) 
4 Microbuchner Filter FMB-52-015, Selas Corp. of America., 
Bliladelpbia., Pa.. 
Urine Collection 
Urines were collected5 approximately every 2 hours for 96 
consecutive hours after tryptophan administration. Aliquots were 
taken for radioactive measurements, paper chromatography, and the rest 
was either extracted or lyophilized on the Virtis Freeze Dryer so as 
to preserve it for future work. 
Extraction Procedures 
Extracts of Urines after Oral Administration 
In order to extract the acidic substances derived from the 
radioactive tryptophan, the pooled 24 hour urine of patient 9, who 
had been pretreated for 6 weeks as described above, was acidified to 
pH 1 with concentrated hydrochloric acid and saturated with salt. 
It was Shaken for ten minutes with an equal volume of isopropyl ether 
and then a second isopropyl ether extract was made. The extracts were 
concentrated on a Rinco evaporator and kept in the freezer until ready 
for counting and paper chromatography. 
Extracts of Urines after Intravenous Administration 
In order selectively to extract the indoleacetic acid from 
urine, three extracts with chloroform were made on the reconstituted 
lyophilized first 8 hour urine of patient 1 who had received intravenous 
injection of the radioactive tryptophan. Prior to Shaking wi tb 
chloroform, the urine was acidified to pH 2 with concentrated hydro-
chloric acid. The extracts were pooled, concentrated and kept in the 
freezer until ready for counting and paper chromatography. 
5we wiSh to "th..ank: Mrs. Twinan, Ward Cl, Medfield State Hospital, 
for her cooperation. 
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Chloroform extracts were made in the same manner of the urine of 
Patient 3 who had also received the radioactive tryptophan intravenously. 
Radioactive Counting Methods 
Planchet Preparation 
One hundred microliter aliquots of the urines were planchetted 
in duplicate and counted on an automatic gas flow counter (Nuclear-
Chicago D47 Ge.s Flow Counter with "M1crom11" window and automatic 
sample changer). All counts were corrected to the same efficiency. 
Self absorption was corrected for by the addition of an internal c14 
tryptophan standard according to the method of Schayer (ll4). 
Scintillation Counting 
One hundred microliter or 1 ml. aliquots of the extracts were 
counted in a Packard Liquid Scintillation Spectrometer, Model 314X. 
To the aliquots were added 4. 0 ml. of absolute ethanol and 10.0 ml. 
of scintillation solution {scintillation grade toluene containing 0.4~ 
of 2,5-diphenyloxazole (DPO) and 0.01~ of 1,4 bis-2-(5-phenyl-Oxazolyl)-
be:nzene (POPOP). All samples were counted in triplicate using 5-dram 
glass vials of low ze..o content. All radioactive counts were corrected 
for quenching by the addition of an internal standard c14tryptophan 
solution. 
Paper Chromatographic Techniques 
The paper chromatographic technique used is a modification of 
that described by Jepson (67). It is the same as that described under 
the section on experimental animals. 
Neat Urines (untreated urines): The equivalent of a 20-second excretion 
sample of urine (approximately 200-500 /' 1.) was spotted. Cochroma-
tography was carried out with such metabolites as 5-hydroxyindoleacetic 
acid, indoleacetic acid, kynurenine, tryptamine, xanthurenic acid, etc. 
Extracts of Urines after o-ral Administration: 
The isopropyl ether extract of the urine of Patient 9 was run 
chromatographically in several systems to separate and identify the 
metabolites. The first series of papers was run in Benzene-Propionic 
Acid-Water (2:2:1) and elution of specific Rf areas was carried out 
with isopropyl acetate. The eluates were counted and then rechromato-
graphed together with synthetic compounds to identify the metabolites 
containing radioactivity. 
The second and third series were run in Benzene-Acetic Acid-
Water (125:72 :3). Those areas seen after spraying the edges with Ehrlich's 
reagent and corresponding in Rf to synthetic indoleacetic acid, 
acetyl-tryptophan and indolelactic acid were clipped and eluted 
with isopropyl acetate and then with methanol. These eluates were 
counted to determine the amount of radioactivity present. The extracts 
and eluates were rechromatographed unidimensionally in Benzene-Formic 
Acid (800:10) together with synthetic indoleacetic acid, acetyl-
tryptophan, and indolelactic acid to determine the metabolic composition 
of the extract (see Table 12, p. 70, and Table 13, p. 71). 
Extracts of Urines after Intravenous Administration: The chloroform 
extracts of the urines of Patients 1 and 3 were chromatographed in 
Benzene-Formic Acid (800:10) (see Table 14, p. 73). Indoleacetic 
acid was cochromatographed at the edges. After spraying the edges with 
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Ehrlich's reagent, the whole region corresponding to indoleacetic acid 
was eluted with methanol and counted. 
In order to further establiSh the identity of the Ehrlich react-
ing material in the chloroform extract with indoleacetic acid, the 
extract plus a known sample of indoleacetic acid were put througn the 
Udenfriend extraction procedure for indoleacetic acid (143) and the 
colored reaction products were measured in the Beckman DK-1 
spectrophotometer. 
Radioautograpnic Techniques 
Radioautograms were made of the neat urines collected up to 
24 hours after tryptophan administration. Radioautograms were also 
prepared from the chromatograms of the isopropyl ether extracts with 
various substances coenromatographed as an aid in identification of 
metabolites. 
The procedure used is identical with that described under the 
section on experimental animals. 
Results 
Recovery of Administered Radioactivity 
Oral Administration 
The mean percent recovery of administered radioactivity after 
the oral administration of cl4 tryptophan to five Chronic schizophrenic 
patients was 31.7~, standard deviation 12.~, range from 13 to 45~ 
(see Table 7 and Tables 29-33 in appendix). The urine was collected 
and counted for 72 hours after tryptophan administration. No 
radioactivity was detectable after 48 hours by the methods employed. 
Fig. 9 is a composite graph for the five :patients on oral administration, 
showing both the mean and the range of the cumulative :percent recovery 
of radioactivity :plotted against time after tryptophan administration. 
Reported in terms of percent of total urinary activity, the mean 
recovery was 68.~ in 8 hours and 93.91> in 24 hours (see Table 35, 
:p. lo4 in appendix). 
Neither pretreatment with non-radioactive L-trypto:phan nor 
administration of a 5 gram load increased the percent recovery of 
administered radioactive count {see Tables 31-33, :pp. 100-102 in 
appendix). 
The biological half life, i.e. the time it takes for one half 
of the total radioactivity recovered to be excreted, was 4.6 hours 
for patients on oral administration (see Table 9). 
Intravenous Administration 
The mean percent recovery of administered radioactivity after 
the intravenous administration of cl4 tryptophan to 4 chronic 
schizophrenic patients was 43.3~, standard deviation 8.5~, range 
from 36 to 58~ (see Table 8 and Tables 25-28, pp. 94-97 in appendix). 
Fig. 10 is a composite curve for the four patients on intravenous 
administration, showing both the mean ar.d the range of the cumulative 
percent recovery of radioactivity :plotted against time after tryptophan 
administration. In ei@:lt hours about a third of the administered 
radioactivity was recovered in the urine. It came out much more 
gradually thereafter and no more was detectable by the methods used 
after 48 hours. Reported in terms of :percent of total urinary activity, 
the mean recovery was 74.2~ in 8 hours and 96.5~ in 24 hours (see 
Table 35, p. lo4). 
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The one normal control 'Who received the tryptophan intravenously 
Showed a total percent recovery of administered count of 35~, no 
different from that of the schizophrenics. 
The mean biological half life was 2. 9 hours for the patients 
on intravenous administration. 
Comparison between Oral and Intravenous Administration 
A comparison of the percent recovery of administered counts 
in the two groups (Tables 7 and 8), and therefore of the recovery of 
D-tryptophan (Table 10) Shows that there is a difference between the 
two groups significant at the 5'J, level. There is also a significant 
difference between the mean biological half lives of the two groups, 
also significant at tb.e 5~ leveL There also appears to be a greater 
variability in the excretion of radioactivity in the patients on oral 
administration. These differences may be due to the different metabolic 
pathways involved as in oral administration there is a greater chance for 
bacterial decomposition of tryptophan in the digestive tract. 
Identification of Radioactive Metabolites 
Neat Urines 
Examination of the radioautograms of neat urine after a 3-month 
exposure Showed the presence of only one radioactive spot, tryptophan; 
in all probability the unmetabolized D-tryptophan. This was true of 
all the subjects, the schizophrenic patients receiving the tryptophan 
orally and intravenously and the normal subject as well. No minor 
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TABLE 7 
RECOVERY OF RADIOACTIVITY FROM URmE OF 
MALE CHRONIC SCHIZOPHRENIC PATIENTS FOLLOWING 
ORAL ADMINISTRATION OF 5 f-<.C OF D ,L- TRYP!'OPHAN-}' -c14 
Patient 
No. 
5 
6 
7 
8 
9 
Orally Administered 
Nonradioactive L-Tryptopnan 
Prior to At time of 
Radioactive Radioactive 
Administration Administration 
Amount Time (grams) 
(grams/ds;r) (weeks) 
0 0 
0 0.5 
2 2 5-0 
2 3 5·0 
2 6 5·0 
Cumulative 
Percent 
Recovery of 
Radioactivity 
21.7 
44.3 
12.9 
45.4 
34.1 
Mean 31.7 
S. D. 12.8 
TABLE 8 
RECOVERY OF RADIOACTIVITY FROM URINE OF MALE 
CHRONIC SCHIZOPHRENIC PATIDTS FOLLOWmG INTRA ~~US 
ADMINISTRATION OF 5 )"-C OF D 1L-TRYPl'OPRAN:)' -C 
Patient 
No. 
1 
2 
3 
4 
Cumulative Percent Recovery 
of Administered Radioactivity 
41.7~ 
31·1 
36.0 
27·6 
Mean 43.3 
S. D. 8.5 
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TABLE 9 
BIOLOOICAL HALF-LIFE OF D 1L-TRYPrOPRAN-j -c14 m MAN 
Mode of 
Administration 
Intravenous 
Patient 1 
Patient 2 
Patient 3 
Patient 4 
Oral 
Patient 5 
Patient 6 
Patient 7 
Patient 8 
Patient 9 
Total Percent Recovery 
of Administered Radioactivity 
41.7 
37·7 
36.0 
57·9 
21.7 
44.3 
13.0 
45.4 
34.1 
Biological Half-Life 
(hours) 
2.5 
2.5 
2.0 
4.5 
Mean 2.9 
4.5 
4.5 
8.5 
3.0 
~ 
Mean 4.6 
TABLE 10 
ESTIMATED RECOVERY OF D-TRYP.rOPHAN FROM URINE OF SCHIZOPHRENIC 
PATIENTS FOLLOWING ADMlNISTRATI<li OF D 1L-TRYP.rOPHAN- j> -c14 
63 
Mode of 
Administration 
Total Percent Recovery 
of Administered Radioactivity 
Estimated Recovery of 
D-Tryptophana 
Intravenous 
Patient 1 
Patient 2 
Patient 3 
Patient 4 
Oral 
Patient 5 
Patient 6 
Patient 7 
Patient 8 
Patient 9 
41.7 
37·7 
36.0 
57·9 
21.7 
44.3 
13.0 
45.4 
34.1 
83.4 
75·4 
72.0 
100.0 
Mean 82.7 
43.4 
88.6 
26.0 
90.8 
68.2 
Mean 63.4 
~e estimated recovery of D-tryptophan must be considered 
maximum since a small portion of the radioactivity may be due to 
metabolites of D- and L-tryptophan. 
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metabolites showed by the .methods used end there is evidence that no 
one metabolite is present to en extent gr-eater than 1~. 
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In order to obtain further information as to what radioactive 
metabolites of tryptophan might be present the extracts were studied. 
Extracts of Urines after Oral Administration of cl4trzytophen 
After a two and one-half month exposure, the radioautogr-am of 
a 2-dimensional paper chromatogram of the isopropyl ether urinary 
extract of Patient 9 was developed, and five radioactive spots were 
found to be present (see Fig. 11). Several of these spots corresponded 
exactly to the chromatograpnic spots which had been identified by Rf, 
color and cochroma.togroapny to be indoleacetic acid (Spot #1), acetyl-
tryptophan (#3), and indolelactic acid (#2). There were also present 
two new spots which will be designated "Unknown Metabolite 1" (# 4) and 
"Unknown Metabolite 2" (#5). See Table 11 for the Rf 1 s and colors 
of these spots. 
In order to confirm the identification of radioactive tryptophan 
metabolites, attempts were made at chroma.togroapnic separation of the 
metabolites by streaking the extract on paper, running it unidimensionally 
and eluting the various areas containing the different metabolites. 
This was done on the 1st isopropyl ether extract which contained 
between 1 and 2~ of the administered radioactivity or about 5~ of 
the urinary activity. 
The first paper chromatogr-aphic separation of the extract in 
Benzene-Propionic Acid-Water (2:2:1) yielded 2 areas in which most of 
the radioactivity was found: Area 1 with an Rf range of .72 to 1.00 
1.oo .9o .so .7o .wo .so AD .30 .zo .10 
Rf IN BUTANOl-ACrTICACID-WATrR 
Fig. 11. J,ad .i.oautoGr'.l.nh ic Map o-f' ~.,.,ots from the l rop onyl 
Ether .E.:xtract of u-~a ~h -hour U!'ilJe of - ~ r t c; follow tnt; the Ai -
rninist""ction of 'S.JA- c cf D _,L-'.::'rypto-ph::n -f -cl4 • ·. 
1.00 
.90 
.so 
.10 
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TABLE 11 
SPOrS APPEARniG IN RADIOAUl'OGRAM OF ISOPROPYL ETHER EXTRACT OF 
24 HOUR URINE OF PATIENT 9 FOLLOWING AD;$!IsrnATION OF 5 )<-c 
OF D 1 L-TRY1TOPHAN-:,.A -C 
Rad.ioauto- Rf . Rf Corresponding Tentative 
graphic Map Isopropanol Butanol- Ehrlich Identification 
~ot No. Ammonia Acetic Acid Color No. 
1 
·52 ·95 99-88 Indoleacetic Acid 
2 
·52 .90 95-88 Indolelactic Acid 
3 ·58 .84 98-89 Acetyl tryptophan 
4 .62 
·95 28-53 Unknown 
Metabolite 1 
5 .67 ·95 28-120 Unknown 
Metabolite 2 
had a count of 6.4 x 104 counts/min. and Area 2 with an Rf range of 
.37 to .72 had a count of 9.9 x lo3 counts/min. (see Table 12)·. The 
two areas were eluted with isopropyl acetate, Chromatographed in 
several systems (see Table 13) and cochromatographed with synthetic 
substances. Area 1 was shown to be predominantly indoleacetic acid 
with some acetyl-tryptophan. Area 2 had about equal amounts of acetyl-
tryptophan and indolelactic acid. 
The above papers were somewhat overloaded and therefore the 
separation was not very good. In order to get better separation of 
the metabolites, another portion of the first isopropyl ether extract 
was chromatographed in 2 separate series in Benzene-Acetic Acid-
Water (125:72:3). These two series showed a much better separation of 
metabolites than had the first and three areas were eluted with 
isopropyl acetate and methanoL Area 1, with an Rf range of about 
.87 to .98 was predominantly indoleacetic acid with much acetyl-
tryptophan present also. The second area, .67 to .87, was almost 
completely acetyl-tryptophan, with a trace of indolelactic acid and 
the third area, Rf .50 to .67, was predominantly indolelactic acid 
with some acetyl-tryptophan. 
Difficulty was encountered in using the Benzene-Propionic 
and Benzene-Acetic acid systems as very poor reproducibility of results 
was obtained. This may be due to the extreme temperature sensitivity 
of these systems because of the large amounts of Benzene present. 
Extracts of Urines after Intravenous Administration 
of cl!l.trrzytophan 
In order more specifically to pin down indoleacetic acid as a 
labelled metabolite of tryptophan, chloroform extracts (which selectively 
TABLE 12 
PAPER CHROMATCGRAHIY (P. C.) OF ISOffiOPYL ETHER EXTRACT OF 24-Hgt.JR URINE 
OF PATIENT 9 FOLLOWING THE OBAL ADMINISTRATION OF 5 ,«.C ( 6.7 x 10 COUNTS/MIN) 
OF D ,L-TRYPI'OPHAN-~-cl4 
24-hgur urine 
2.3 x 10 counts/min 
pH 1, salt sat'd. 
I 
1st Isoprop{l ether extract ' 
9.3 x 10 counts/min J 
l~ -----.._,...._~-P. C. Series II 
Benzene-rropionic Acid-Water Benzen~-Acetic Acid-Water 1 Benzene4Acet1c Acid-Water 3.7 x 10 counts/min spotted 1 1.8 x 10 counts/min spotted I 1.2 x 10 counts/min spotted 
r I-;;-oprop; l ~te elution I Is~;i A-;;;-tate' IMathe.nol ElutionJ I sopropyl Acetate' Methanol Eluti~-
1 I I --~- :---1 ...________., I I 1 I Area Area 2 Area 3 Area 1 · Area 2 1 Area 3 Area 1 Area 2 ~ Area 3 1 
Rr .72 lr. ~ .37-.72 'Rr .27-.27 Rr .87-.98 Rr .67-.87i ~ .52-.67 I~ .90-.97 IRr .75-.90 f .50-.75 
6.4 X 1~ 9.9 X lo' 10.6 X lo' 3.9 X loJ 3.4 X loJ 2.1 X loJ 1 2.9 X lcQ 1.3 X lo' 1.1 X lo' 1 
I
I counts/min counts/min counts/min counts/min counts/minj counts/min counts/min ·counts/min !counts /min 
_ IAA(+AcT) AcT + ILA j I IAA(+ AcT) AcT I ILA(+ AcT) IAA(+ AcT) AcT( + ILA) ILA( + AcT) i 
--.:j 
0 
J 
TABLE 13 
PAmR CHROMATClGRAPHIC IDENTIFICATION OF URINARY METABOLITES 
OBTAJNED FROM AN ISOPROPYL ETHER EXTRACT OF URINE OF PATf1iNT 9 
FOLLOWING ORAL ADMINISTRATION OF D 1 L-TRYPXOPHAN-.J -cl 
R:e Values of Radioactive Metabolites 
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Indoleacetic Acid Acetyl Tryptopnan Indolelactic Acid 
Authentica Urinary Authentic Urinary Authentic Urinary 
Isopropanol 0.30 .31 .41 .40 .;1 
Ammonia-Water 
Butanolb .g-r .96 
·92 ·93 .90 
Acetic Acid-Water 
Benzene .71 .71 .40 .42 .20 
Propionic Acid-Water 
Benzene .78 ·19 ·55 ·52 .29 
Acetic Acid-Water 
Benzene .41 .42 .03 .03 .o4 
Formic Acid-Water 
aSynthetic material chromatographed with urinary extract. 
bThe three compounds were not run on the same sheet so the 
comparative Rt's are not as reliable as those reported for the other 
solvent systems. 
·35 
.90 
.21 
.;o 
.02 
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extract indoleacetic acid) (143) were made of the reconstituted lyo-
philized first 8 hour urines of Patients 1 and 3. These two patients 
were chosen for two reasons: they had received no tryptophan load, 
thus avoiding dilution of the radioactive material, and they had 
received the tryptophan intravenously allowing for maximum tissue 
metabolism rather than metabolism by intestinal bacteria. 
A solvent system was needed which would give a good separation 
of indoleacetic acid from other metabolites suCh as acetyl-tryptophan 
and indolelactic acid. The Benzene-Formic Acid {800:10) system was 
developed as indoleacetic acid is the only substance of those tested 
that moves some distance in it with acetyltryptophan and indolelactic 
acid remaining almost stationary {see Table 36, p. 105 in appendix). 
When the extracts were chromatographed in Benzene-Formic Acid, 
indoleacetic acid was found to be the only Ehrlich positive substance 
present {see Table 14). When this area of the chromatograms (Rf .17 
to .35) was eluted with methanol and counted, it was found to be radio-
active. The 3X chloroform extract of the reconstituted first 8 hour 
urines contained about 0. 5'/o of the radioactivity. The eluted indole-
acetic acid area of the extract contained 0.15~ of the count in the 
original extracted urine. 
As further proof that the radioactive indolic material in the 
extract was indoleacetic acid, the extract and a known sample of 
indoleacetic acid were put through the Udenfriend procedure (143) 
for the selective extraction of indoleacetic acid, and the colored 
reaction products were measured on the Beckman DK-1 Spectrophotometer. 
TABLE 14 
PAPER CHROMATOGRAPHY OF CHLOROFOBM EXTRACTS OF 24-BOUR 
URINE OF PATmTS 1 AND 3 FOLLOWJNG m.rRA VENO~~ 
ADMINisrRATION OF 5 ;«- c of D ,L-TRYPI'OPHAN-j -C 
Pa~ient 1 (7.6 x 10 counts/min) 
administered 
-·--
--1· 8 ho urine 1.2 x lOgrcounts/min 
pH 2 
I 
j Chloro~rm Extract . __ 5·4 x 1 counts/min 
I -
Paper Chromatography 
Benzene-Formic Acid 
.; x lo3 counts(~ spotted 
I 
l Methanol Elution of area ~L·!]-·35 ·-~~~~~=a/min I 
Pa~ient 3 (8.3 x 10 counts/min) 
administered 
8 hogr urine 
0.7 x 10 counts/min I 
pB2 
·"'----:--~-~~ 
I ~~l:-~~~a::i.1.. 
··j--Pa~p-er-Chr-~oma-l~t-ogr- apb.~y ~----,1 
Benzene-Formic Acid 
~ .4 x leO counts/min spotted j 
J 
' __ .Me_ th_ an_o_l_,__El_u_t_i_on __ ~l 
of area Rf .17-.35 
--- -·-· -=r- ---- . 
l_l.l X lo3~~ts/ml~ 
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Both the authentic indoleacetic acid and the extracts Showed a peak at 
about 510 lamdas (see Fig. 12). 
Identification of Metabolites of 
Tryptophan by Non-Radioactive Methods 
Althougn neither pretreatment with non-radioactive L-tryptophan 
nor administration of a 5 gram load of non-radioactive L-tryptophan 
increased the percent recovery of administered radioactive count, 
the chromatograms of some of the patients under a 5 gram load showed 
an increase in size and intensity of color of the tryptophen, 
indoleacetic acid, 5-hydroxyindoleacetic acid and xanthurenic acid 
spots as well as the appearance of 4 new Ehrlich reacting spots 
identified as acetyltryptophan, acetylkynurenine, kynurenine and 
kynurenic acid (see Table 15). The new spots 1J1a3 be endogenously 
present but were not detected under these conditions. 
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TABLE 15 
PAPER CHROMATOGRAPHIC IDENTIFICATION OF URINARY 
METABOLITES FOLLOWING ORAL ADMINISTRATION OF 
A 5 GRAM LOAD OF NON-RADIOACTIVE L-TRYPl'OPHAN 
Rf Values of Metabolites 
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Isopropanol- Butanol-Acetic Ehrlich 
Ammonia-Water Acid-Water Color 
Tryptophan a 98 Authenticb 
.30 
·53 UrinaryC 
.22 
·54 
Indoleacetic Acida 
Authentic 
.45 
·90 
Urinary .41 
·92 
5-Bydraxyindoleacetic Acida 82 
Authentic .22 
·78 
Urinary .16 .80 
Xanthurenic Acida 97(NDBB 
Authentic .03 
·54 spray) 
Urinary .02 
·53 
Acetyl tryptophan 91 
Authentic 
·50 .89 
Urinary 
·55 .90 
lcynurenine 36 
Authentic .20 .52 
Urinary .22 
·52 
Acetylkynurenine .25 
Authentic 
Urinary .47 .82 
Icynurenic Acid 123 ---? 112 
Authentic .40 .62 (Dragendorf 
Urinary .41 .65 Spray) 
ar:nese substances were detected prior to tryptoPhan administration, 
i.e. endogenously. Other substances such as kynurenine, acetyl tryptophan, 
etc. are probably endogenously present but were not detected under our 
conditions. 
bValues obtained by cochromatographing synthetic materials with 
the neat urines. 
cValues obtained from 2-dimensional chromatograms of endogenous 
material in neat urine. 
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CHAPI'ER IV 
DISCUSSION 
In this study , urine of rats and of man was analyzed for 
metabolites of tryptophan with radioactivity used as a marker. 
D, L- tryptophan was used because of the unavailability of the labelled 
L form. 
The ra.dioautograms of neat human urine showed the major 
radioactive metabolite to be tryptophan and there is evidence that 
no other metabolite is present to an extent greater than l'fo. As 
Sarrett and Goldsmith (ll2) showed that subjects ingesting 2 . 5 or 5.0 
grams of L- tryptophan excreted only about 0.6~ of the dose as free 
tryptophan in the urine, it can be assumed that virtually all the 
labelled tryptophan in the urine occurs as the D form. Langner and Berg 
(78) found 1/3 to 1/2 of a 2 gram dose of D- tryptophan excreted unchanged 
in the urine. Table 10, p. 6;, indicates that some of the D-tryptophan 
must have been metabolized as not all of it is excreted unchanged. 
The present study c onfirmed the general knowledge of the 
utilization of D- and L- tryptophan in humans and in rats. That is, 
that althougn rats preferentially metabol ize the L form, they also 
utilize D- tryptophan (12) due to their possession of the enzyme necessary 
to invert the D to the L form. This is evidenced by only small amounts 
of labelled tryptophan being recovered in the rat urine and the occurrence 
of 40 labelled metabolites derived from the tryptophan . Man is 
known to metabolize D-tryptophan poorly with only a few metabolites 
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having been found to be derived from it such as D-kynurenine, indolepyruvic 
acid, acetyl-D-tryptophan, and small amounts of kynurenic acid, 
xanthurenic acid, and pyridone suggesting that some of the D form is 
converted to nicotinic acid (78, 98). None of these metabolites were 
recovered in this study probably due to the fact that they are 
produced in such small quantities and excreted over a long period of 
time and were therefore not detectable by the methods employed. 
In the studies carried out to date, a very small percentage of 
the tryptophan intake lias been accounted for. The presence of only 
1-2~ of the original radioactivity was accounted for in this study. 
A probable explanation for this sparse knowledge of what happens to 
the tryptophan is indicated by the results with rats where forty 
labelled metabolites were found. This indicates that the tryptophan 
is fragmented into at least 40 different segments and the technical 
difficulties involved in picking up the metabolites occurring in such 
small quantities can be appreciated. In humans the endogenous material 
is probably fragmented in this mann.er into many parts; the administered 
material is first absorbed by the proteins of the body pool, then 
fragmented and excreted over a long period of time in quantities too 
small to be detected by the methods used in this study. 
In this radioautographic study of the metabolism of D ,L-tryptophan-
) -c14 in rats, the mean percent recovery of radioactivity in all eight 
rats was found to be 4.4~. Of the forty radioactive metabolites present 
on the radioautograms, eight were tentatively identified as: 
acetyltryptophan, 5-hydroxyindoleacetic acid, 6-hydroxyskatole sulfate, 
indoleacetic acid, indoleacetylglycine, indolecarboxylic acid, kynurenic 
acid, and xanthurenic acid. 
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Using the same techniques employed with the rats, that is, 
extraction procedures, a modification of Jepson's (67) paper chromato-
graphic technique, and radioautography, it was found that after adminis-
14 tration of D ,L-tryptopb.an-:,8 -C to man, an isopropyl ether extract of 
the pooled 24-hour urine of one patient Showed the presence of l-2i of 
the original radioactivity. There also was radioactive evidence for 
the following metabolites: acetyltryptophan, indoleacetic acid, 
indolelactic acid, and 2 unknown metabolites. Paper chromatography 
was used ·to separate and confirm the identification of these metabolites. 
A chloroform extract of the urines of two patients who had received 
the tryptophan intravenously selectively extracted the indoleacetic 
acid. This was shown to be radioactive and there is both chromatographic 
and colorimetric proof of its purity and identity. 
In examining these data, there appears to be a significant 
difference between the patients receiving the tryptophan orally and 
those receiving it intravenously in the recovery of administered 
counts, the recovery of D-tryptophan, and in the biological half-life 
of the radioactive tryptophan. There also appears to be a greater 
variance in the urinary excretion of radioactivity in the patients on 
oral administration. These differences may be due to the different 
metabolic pathways involved as in oral administration there is more 
chance for bacterial decomposition of tryptophan in the gut. 
The probable reasons for finding forty labelled metabolites in 
the neat urine of rats and only labelled tryptophan in the neat urine 
of humans are several: first, the rat utilizes the D-tryptophan as 
well as the L so if the rat and human were given equal doses, in effect 
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the rat would be getting twice the effective dose . Much greater amounts 
of radioactivity were administered to the rats as there are AEC 
restrictions as to the amount of radioacti vity that can safely be 
given to man - - 25 ;P c were administered to a rat as opposed to 5 /fC 
to a human. From a comparison of the body weights of the tv.To, it can 
be seen hmr much greater a dose per body weight was administered, i.e. 
125 fL C/kg body w·eight to the rat and • 066 ;tc/kg to the human. If 
one takes the above mentioned difference in utilization of D- tryptophan 
into account it would be almost a ratio of 125 ~c/kg to . 066 ,,ac/kg. 
Also, the rat excretes a very concentrated urine as compared to man 
and therefore has a much higher concentration of metabolites. 
The one and only radioactive spot that appeared in the radio-
autograms of neat human urine has been positively identified as tryptophan, 
probably D- tryptophan which is poorly metabolized by man. Apparently none 
of the L-tryptophan can be accounted for . The tryptophan may have been 
metabolized and diluted in the body pools . The diluted radioactive pro-
ducts then are excreted over a long period of time and at levels below 
those which can be measured; this dilution effect probably accounts for 
most of the L- tryptophan. There is little doubt that part of the tryptophan 
is excreted in the feces and part profoundly degraded to carbon dioxide . 
To carry out significant studies of radioactive tryptophan 
metabolism in humans, it would be necessary to obtain labelled L-
tryptophan and perhaps administer 10 or more microcvxies instead of 5· 
This would increase the amount of c14 L- tryptophan administered, 
perhaps to the extent where one could detect the presence of further 
radioactive metabolites . 
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In man, the administration of a 5-gram load of non-radioactive 
L-tryptophan had no effect on the per cent recovery of administered 
radioactive count although the chromatograms did show an increase in 
size and intensity of color of tryptophan, indoleacetic acid, 
5-hydroxyindoleacetic acid and xanthurenic acid as well as the 
appearance of 4 new Ehrlich reacting spots identified as acetyltryptophan, 
kynurenine, acetylkynurenine, and kynurenic acid. These spots were 
largely derived from the non-radioactive L-tryptopnan as we were unable 
to detect any radioactivity in them. 
The recovery of radioactive count in man showed no differences 
between the schizophrenic patients and the one normal control, the 
average percent recovery for the patients on oral administration 
being 32tfo with a range of from 13 to 45tfo and the average percent 
recovery for those receiving the material intravenously was 43~ with 
a range of from 36 to 5&{o. The one normal control who received the 
tryptophan intravenously showed a 351o recovery, which is no different 
from that of the schizophrenic patients. Nor did his radioautograms 
show the appearance of any but the one radioactive spot of tryptophan 
as appeared on the radioautograms of the schizophrenics. 
Although this study provides no information on the effect of a 
load on normal persons as against schizophrenic patients, it is 
interesting to note that in other load studies such as that of 
Zeller (150), differences between schizophrenics and normals have been 
claimed in the metabolism of a tryptophan load. Kopin (74), however, 
found no differences. 
llie two unknown metabolites found in the isopropyl ether 
extract of human urine had Rf' s of • 62/. 95 and • 67/.95, having just 
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a sli~tly higher Rf in isopropanol ammonia and in butanol acetic 
acid than acetyltryptophan and having the same Rf in butanol acetic 
and a little higuer one in isopropanol ammonia than does indoleacetic 
acid. The color of both these spots was originally rose but after 
fading, the residual color was a tannish gray. Examination of' the 
radioautogram showed that both these spots were "hotter" than 
indoleacetic acid. 
In the literature other reports have appeared of unknown 
metabolites of tryptophan following the ingestion of the D ,L form. 
Thus, Albanese and Frankston (2) in 1944 reported an "aberrant metabolite" 
which they concluded was a metabolite of the D isomer as none of the 
"aberrant metabolite" was excreted after ingestion of L-tryptophan. 
Langner (78) showed this "aberrant metabolite" to be unmetabolized 
tryptophan, presumably the D isomer. Sarrett and Goldsmith· (112) 
reported on an unknown, ether-extractable metabolite on administration 
of D,L-tryptophan which they felt was also probably a metabolite of 
D-tryptophan. Armstrong and Robinson (5) consider that this ether 
soluble unknown of Sarrett and Goldsmith is probably indolelactic acid. 
The identification of unknown metabolites of tryptophan and the 
determination of their importance in the functioning of the organism 
remains an area of fruitful investigation. 
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CHAPI'ER V 
SUMMARY 
Tryptophan and its metabolites have been implicated in va~ious 
mental disorders including schizophrenia. This serious disease of unknmm 
etiology has become an increasingly important subject of biochemical 
investigation. In order to understand more fully the metabolism of 
tryptophan in schizophrenia, an investigation of urinary metabolites 
was undertaken, utilizing radioactivity as a marker. 
Rats were studied to perfect the techniques and to provide 
possible indications of the metabolites to be looked for in man. 
Tryptophan was administered to humans orally, to duplicate the normal 
route of intake, and intravenously, to obtain indications of tissue 
activity without the tryptophan having been acted on by intestinal 
bacteria. 
The techniques employed vere a combination of two-dimensional 
ascending paper chromatography and radioautography. The latter was 
useful in the visual identification of the urinary metabolites of 
radioactive c14- labelled tryptoPhan. Through the use of extraction 
procedures vith various solvents, selective separation and identification 
were made possible. Concentration of the extracts provided for the 
detection of substances present in only minute quantities. 
Upon administration of D,L-Tryptophan-~ -cl4 to rats and to man, 
the following results were obtained: the mean percent recovery of 
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radioactivity in the rats was 4.4~. Of the forty radioactive spots 
found in the radioautograms, eight were tentatively identified as: 
acetyltryptophan, 5-hydroxyindoleacetic acid, 6-hydroxyskatole sulfate, 
indoleacetic acid, indoleacetylglycine, indolecarboxylic acid, kynurenic 
acid, and xanthurenic acid. Some unm.etabolized tryptophan was also excreted. 
In the schizophrenic patients who received the tryptophan orally, 
there was a mean percent recovery of radioactivity of 32~ . In those who 
received the tryptophan intravenously, the recovery was 43~ . The radio-
autograms of human urines showed the presence of only one spot, tryptophan, 
probably the D form which is poorly metabolized in man. A normal control 
showed no difference from schizophrenic patients in recovery of radio-
activity or in the radioautograms. 
Isopropyl ether extracts of one of the human urines showed the 
presence of 1-2~ of the original radioactivity. Radioautograms of the 
extracts showed the presence of labelled acetyltryptophan, indoleacetic 
acid, indolelactic acid and two unknown metabolites. A chloroform 
extract of some of the human urines selectively extracted the indoleacetic 
acid. This was shown to be radioactive and both chromatographic and 
colorimetric evidence was obtained of its purity and identity. 
'llo further establish the metabolic patterns of tryptophan in 
schizophrenia, methods must be developed to identify the fragments of 
tryptophan which are incorporated in the body proteins and then slowly 
excreted at levels too low to be detected by current methods. I t is 
hoped that labelled L-tryptophan will become available so that the 
metabolism of tryptophan in both normal persons and schizophrenic 
patients can be further delineated. 
APP.ENDlX 
TABLE 16 
BECOVERY OF RADIOACTIVITY FROM URlNE OF A RAT 
FOLLO~G INTRAmRITONEAL ADMINiffilRATION OF ~5 ,a..c 
(25 .1 x 10 COUNTS/MIN. ) OF D1 L-TRYPl'OPHAN-)'-C1 (RAT 1) 
Time after Cumulative counts in Cumulative percent recovery 
Administration urine {counts/min. ) of administered radioactivity 
{hours) 
4.5 2. 90 X 105 1.2~ 
24 6.16 X 105 2.4 
48 7.27 X 105 2. 9 
72 7. 86 X 105 3.1 
96 2. 28 X 105 3.3 
120 8. 82 X 105 3·5 
144 9.14 X 105 3. 6 
168 9.29 X 1o5 3 ·7 
TABLE 17 
RECOVERY OF RADIOACTIVITY FROM URWE OF A EAT 
FOLLOW~G INTRA:EERITONEAL ADMllUSTRATION OF y~ )i. c 
(25.1 x 10 COUNTS/MIN.) OF D ,L-TRYPI'OPHAN-_..8 -C (RAT 2) 
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Tims after Cumulative counts in Cumulative percent recovery 
Administration urine (counts/min.) of administered radioactivity 
(hours) 
4.5 0.60 X 106 2 . 4% 
24 1.00 X 106 4 . 0 
48 1.09 X 106 4 .4 
72 1.22 X 106 4.8 
96 1.28 X 106 5·1 
120 1.35 X 10
6 
5· 3 
144 1.39 X 106 5 · 5 
168 1.42 X 106 5 · 6 
TABLE 18 
RECOVERY OF RADIOACTIVITY FROM URINE OF A RAT 
FOLLOW~G JM'RAP.ERITONEAL ADMINISTRATION OF l~ fL O 
(25.1 x 10 COUNTS/MIN.) OF D ,L-TRYPrOPHAN-)' -C (RAT 3) 
Time after Cumulative counts in Cumulative percent recovery 
Administration urine (counts/min.) of administered radioactivity 
(hours) 
4.5 0.41 X 10 
6 1.6~ 
24 1.11 X 106 4.4 
48 1.25 X 10 6 5·0 
72 1.34 X 106 5·3 
96 1.39 X 10 6 5·5 
120 1.44 X 106 5·7 
144 1.45 X 106 5.8 
168 1.51 X 106 6.0 
TABLE 19 
RECOVERY OF RADIOACTIVITY FROM URINE OF A RAT 
FOLLO~G INTRAPERITONEAL ADMmiSTRATION OF f"' ,.t-<c 
(25.1 x 10 COUNTS/MIN.) OF D,L-TRYPrOPHAN-~ -C ~ (RAT 4) 
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Time after Cumulative counts in Cumulative percent recovery 
urine (counts/min.) Administration of administered radioactivity 
(hours) 
4.5 l.Ox1o5 0.7i 
24 4.5 X 1o5 3.1 
48 5.6 X 1o5 3·7 
72 6.4 X 105 4.2 
96 6.7 X 105 4.5 
120 7.0 X 105 4.6 
144 7•3 X 105 4.8 
168 7 •5 X 1o5 5·0 
TABLE 20 
RECOVERY OF RADIOACTIVITY FROM URmE OF A RAT 
FOLLOWING OO'RAPERTrONEAL ADMI:NISTRATION OF f~ )Lc (15.5 x 106 COUN!'S/MI:N.) OF D 1L-TRYPrOPHAN-,& -C (RAT 5) 
Time after Cumulative counts in Cumulative percent recovery 
Administration urine (counts/min.) of administered radioactivity 
(hours) 
24 4.63 X 105 3-~ 
48 5·35 X 1o5 3.4 
72 5·93 X 105 3.8 
96 6.31 X 105 4.0 
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TABLE 21 
:RECOVERY OF RADIOACTIVITY FROM URlNE OF A RAT FOtf'OWING 
INTRAPERITONEAL ADMINISTRATION OF 15 _llc 41.5.5 x 10 COUNTS/MIN) 
OF D 1 L-TRYPrOPHAN- ;8-C1 (RAT 6) 
Time after Cumulative counts in Cumulative percent recovery 
Administration urine (counts/min.) of administered radioactivity 
(hours) 
24 4.00 X 1o5 2.6'/o 
48 4.63 X 1o5 3.0 
72 5.13 X 1o5 3.3 
96 5.42 X 1o5 3·5 
T.ABLE 22 
RECOVERY OF RADIOACTIVITY FROM URmE OF A RAT 
FOLLOW~G mrRAPERITO:NEAL AD:taNISTRATION OF 1~ e_c 
(15.5 x 10 COUNTS/MIN.) OF D,L-TRYPrOPHAN-~ -c1 (RAT 7) 
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Time after Cumulative counts in Cumulative percent recovery 
Administration 
(hours) 
urine (counts/min.) of administered radioactivity 
24 3·55 :z: 105 2.:;'f, 
48 4.17 X 105 2.7 
72 4.56 X 1o5 2.9 
96 4.86 X 1o5 :;.1 
TABLE 23 
RECOVERY OF RADIOACTIVITY FROM URINE OF A RAT 
FOLLOW~ OO'RAPERITONEAL AD!vfiNISTRATION OF I~~ c 
(15.5 x 10 COUNTS/MIN. ) OF D ,L-TBYP.rOPRAN-~-C (RAT 8) 
Time after Cumulative counts in Cumulative percent recovery 
Administration urine (counts/min. ) of administered radioactivity 
(hours) 
24 5.34 X 1o5 3.4% 
48 6 . 08 X 105 3·9 
72 6.60 X 1o5 4.2 
96 6.91 X 1o5 4 . 4 
TABLE 24 
!EroENT OF TCY.rAL URINARY RADIOACTIVITY 
FOUND AFrER 24 AND 48 hours IN 8 RATS 
Percent Urinarl Activitz after 
24 Hours 48 Hours 
Ba.t1 64.~ 78.4'f, 
Rat 2 71.4 78.5 
Rat 3 73·3 83.3 
Rat 4 62.0 74.1 
Rat 5 75·0 85 . 0 
Rat 6 74.3 85.7 
Rat 7 74.2 87.1 
Rat 8 77·3 88.6 
Average 71.6~ 82.6% 
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TABLE 25 
RECOVERY OF RADIOACTIVITY FROM URINE OF A MALE CHRONIC 
SCHIZOPHRENIC PAT~T FOLLOWING INTRA VENOUS .ADMLNIS'rRATIOff 
OF 5 fo c (7.61 :x 10 COUNTS/MIN.) O.F D1 L-TRYPl'OPHAN-p' -C1 
/ (PATIENT 1) 
Time a.:fter Cumulative Counts in Cumulative percent recovery 
Administration Urine {counts/min.) of administered radioactivity 
{hours) 
2 1.25 :X 106 16.4~ 
3 1. 73 :X: 10 
6 22.8 
4 2.02 :X 10 6 26.5 
6 6 2.25 :X 10 29.5 
8 
6 2.49 :X 10 32.7 
16 2.79 X 10 6 36.7 
24 6 2.95 X 10 38.7 
32 3.07 X 10 6 40.3 
40 3.12 X 106 41.1 
48 3.17 :X 106 41.7 
72 3.17 X 106 41.7 
TABLE 26 
RECOVERY OF RADIOACTIVITY FROM URINE OF MALE CHRONIC 
SCHIZOPHRENIC PAT~T FOLLOWING INTRA VENOUS AD.MlNISTBATiffi 
OF 5/ c (8.85 x 10 COUNrS/MIN.) OF D,L-TRY!TOPHANj6-C 
(PATlENX 2) 
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Time after Cumulative counts in Cumulative percent recovery 
urine (counts/min.) Administration of administered radioactivity 
(hours) 
1.5 1.28 X 106 14.5'fo 
3·5 2.01 X 106 22.7 
9 2.54 X 106 28.7 
18 6 3.09 :X: 10 34.9 
22.5 6 3.21 :X: 10 36.2 
25 3.26 X 106 36.8 
31 3.34 X 106 37·7 
48 3.34 :X: 106 37·7 
TABLE 27 
RECOVERY OF RADIOACTIVITY FROM URINE OF A MALE CHRONIC 
SCHIZOPHRENIC PAT~T FOLLOWING IM'RA VENOUS ADMINISI'BATION 
OF 5 P.- c (8.27 x 10 COUNTS/MIN.) OF D,L-TRYPI'OPHAN-j9-C14 
/ (PATIENT 3) 
Time after Cumulative counts in Cumulative percent recovery 
Administration urine (counts/min.) of administered radioactivity 
(hours) 
2 1.53 X 106 18.5% 
3·5 1.73 X 106 20.9 
6 2.19 X 106 26.4 
8 2.50 X 106 30.2 
12 2.67 X 106 32.2 
22 2.95 X 106 35.8 
24.8 2.97 X 106 36.0 
48 2.97 X 106 36.0 
TABLE 28 
RECOVERY OF RADIOACTIVITY FROM URJEE OF A MALE CHRONIC 
SCHIZOPHRENIC PAT~ FOLLOWING 1m'RA VENOUS ADMINISTRATI~n 
OF 5 .u. c (7.86 x 10 COUNTS/MIN.) of D1 L-TRYPI'OPHAN-j9 -C1 
/ (PATIENT 4) 
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Time after Cumulative counts in Cumulative percent recovery 
urine (counts/min.) Administration of administered radioactivity 
(hours) 
2 1. 91 :X 106 24.3"f, 
8 2.66 :X 106 33.8 
12 3.82 :X 106 48.6 
20 6 4.33 X 10 55·1 
22.5 4.34 :X 10 6 55·2 
24 4.38 :X 106 55.8 
26.5 4.39 :X 106 55·9 
27·5 4.43 X 10 6 56.4 
31.5 4.44 X 106 56·5 
36 4.49 :X 106 57·3 
43.5 6 4.54 X 10 57·9 
72 4.54 X 106 57·9 
TABLE 29 
RECOVERY OF RADIOACTIVITY FROM URINE OF A MALE CHRONIC 
SCHIZO~IC PATIENT FOLLOWING ORAL ADMINISTRATION OF 5/' c 
(7.0 x 10 COUNTS/MIN.) OF D,L-TRYPrOPHANj1.3 -C14 (PATlENT 5) 
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Time after Cumulative counts in Cumulative percent recovery 
urine (counts/min. ) Administration of administered radioactivity 
(hours) 
1 0.21 X 106 3.CJ!, 
3 0.46 X 10 6 6.6 
4.5 0.75 X 106 10.8 
5·5 0.85 X 106 12.2 
10.5 1.09 X 10 6 15·7 
16 1.25 X 106 17.9 
20 1.33 X 106 19.1 
24.5 1.38 X 106 19.8 
35 1.46 X 106 21.0 
69 1.52 X 10 6 21.7 
96 6 1.52 X 10 21.7 
TABLE 30 
RECOVERY OF RADIOACTIVITY FROM URINE OF A MALE CHRONIC 
SCHIZOPHRE~IC PATIENT FOLLOWING ORAL ADMINISXRAT~ON OF 5,ft c 
(7.72 x 10 COUNTS/MIN.) OF D,L-TRYPI'OPHAN;:4 -Cl (PATIENT 6)a 
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Time after Cumulative counts in Cumulative percent recovery 
urine (counts/min.) Administration of administered radioactivity 
{hours) 
1.5 0.61 X 106 7·':JI, 
4 1.69 X 106 21.9 
9 2.43 X 106 31.5 
6 37·7 19 2.91 X 10 
22 3.22 X 106 41.7 
24 3.26 X 106 42.2 
27 3.29 X 106 42.6 
29 3.30 X 106 42.8 
36 3.36 X 106 43.5 
44 3.42 X 106 44.3 
72 3.42 X 10 6 44.3 
a Concurrently with the administration of the radioactive material, 
the patient was given an oral 0.5 gram load of non-radioactive 
L-tryptophan. 
TAJ3LE 31 
RECOVERY OF RADIOACTIVITY FROM URINE OF A MALE CHRONIC 
SCHIZO~IC PAT lENT FOLLOWlNG ORAL ADMlNisrFA:ftON OF 5"" c 
(7.60 x 10 COUNTS/MIN.) OF D,L-TRYPI'OPIWi-fc" -C (PATlENT 7)a 
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Time after Cumulative counts in Cumulative percent recovery 
urine (counts/min.) Administration of administered radioactivity 
(hours) 
1.5 O.o426 X 106 0.56rip 
2.5 6 0.111 X 10 1.5 
3·5 0.247 X 106 3.3 
5 0.345 X 10 
6 4.5 
7·5 6 0.405 X 10 5·3 
10.5 0.532 X 106 7·0 
19.5 6 0.702 X 10 9.2 
22 6 0.760 X 10 10.0 
23 6 0.808 X 10 10.5 
24 0.821 X 10 6 10.8 
26.5 0.854 X 106 11.2 
29 0.872 X 106 11.5 
32 0.910 X 106 12.0 
34.5 0.934 X 10 6 12.3 
44.5 6 0.984 X 10 13.0 
72 0.984 X 106 13.0 
~e patient was pretreated for two weeks with non-radioactive 
L-tryptophan, 2 grams/day administered orally. Concurrently with the 
administration of the radioactive material, the patient was given an 
oral 5.0 gram load of non-radioactive L-tryptophan. 
TABU: 32 
RECOVERY OF RADIOACTIVITY FROM URINE OF A MALE CHRONIC 
SCHIZO~IC PATlENT FOLLOWING ORAL ADMINISTRAIION OF 5ft c 
(6.75 x 10 COUNTS/MIN.) OF D 1L-TRYPI'OPHAN;8 -C (PATIENT 8)a 
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Time after Cumulative counts in Cumulative percent recovery 
Administration urine (counts/min.) of administered radioactivity 
(hours) 
1.5 0.499 X 10 6 7.4~ 
2 1.20 X 106 17.8 
3 1.65 X 10 6 24 . 5 
4 1.94 X 106 28.7 
5·5 2.23 X 106 33.1 
7·5 2.43 X 106 35·9 
8.5 2.69 X 106 39.8 
6 40.5 9·5 2.74 X 10 
11 
6 2.82 X 10 41.8 
12.5 2.89 X 106 42.7 
15 2.91 X 10 6 43.0 
19.5 3.04 X 106 45.0 
22.5 3.07 X 106 45.4 
48 3.07 X 106 45.4 
~e patient was pretreated far 3 weeks with non-radioactive 
L-tryptophan, 2 gra:ms/dey administered orally. Concurrently with the 
administration of the radioactive material, the patient was given an 
oral 5· 0 gram each of non-radioactive L-tryptophan. 
TABLE 33 
BECOVERY CIF RADIOACTIVITY FROM UIUNE OF A MALE CHRONIC 
SCHIZO~UC PATIENT FOLLoWING ORAL ADMINISTRAJfiON OF 5?-' c 
(6.7 x 1oJ COUNTS/MIN.) OF D,L-TRY1TOPHAN-j.9 -c1 (PATIENT 9)a 
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Time after Cumulative counts in Cumulative percent recovery 
urine (counts/min.) Administration of administered radioactivity 
(hours) 
1.5 0.59 X 106 8.~ 
2.5 6 1.06 X 10 15.8 
3.5 1.60 X 106 23.9 
4.5 1.90 X 106 28.4 
7·5 1.94 X 10 6 29.0 
9·5 6 2.06 X 10 30.8 
10.5 6 2.10 X 10 31.3 
12 6 2.14 X 10 32.0 
20 2.29 X 106 34.2 
48 2.29 X 106 34.2 
~e patient was pretreated for 6 weeks with non-radioactive 
L-tryptopb.an, 2 gra:ms/dey, administered orally. Concurrently with 
the administration of the radioactive material, the patient vTas given 
an oral 5. 0 gram load of non-radioactive L-tryptophan. 
TABLE 34 
RECOVERY OF RADIOACTIVITY FROM URINE OF A NORMAL SUB~ 
FOLLOvllNG INTRAVENOUS ADMllUsrRATION OF 5,.1-l- c (~~58 x 10 
COUNTS/MIN.) OF D.,L-TRYPI'OPRANp -C 
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Time after Cumulative counts in Cumulative percent recovery 
Administration urine (counts/min.) of administered radioactivity 
(hours) 
1.5 1.03 X 106 12.1% 
3·5 1.52 X 10
6 17.7 
7.0 2.00 X 106 23.3 
9·5 2.28 X 106 26.6 
20 6 2.81 X 10 32.8 
24 2.91 X 106 33.9 
26 2.96 X 106 34.6 
48 2.96 X 10 6 34.6 
TABLE 35 
PERCENT OF TorAL URINARY RADIOACTIVITY FOUND 
AFI'ER 8 AND 24 HOURS IN HUMAN URINES 
Percent Urinary Activitl after 
8 Hours 24 Hours 
Intravenous 
Administration 
Patient 1 78.4~ 92·&fo 
Patient 2 76.1 97.1 
Patient 3 83-9 99-9 
Patient 4 58.4 96.3 
Average 74.2~ 96-5% 
Oral 
Administration 
Patient 5 64.5 91.2 
Patient 6 71.1 95-2 
Patient 7 40.8 83.1 
Patient 8 83-5 100.0 
Patient 9 84.8 100.0 
Average 68.~ 96.5~ 
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TABLE 36 
Rf 1 S OF SYNTHETIC TRYPI'OP.IIAN METABOLITES AND RELATED INDOLES 
Compound Rf 
Iso-Propanol N-Butanol Benzene Benzene Benzene 
Ammonia Acetic Acid Proprionic Acetic Acid Formic Acid 
Water Water Acid Waterb (80:1) 
(20:1:2) (12:3:5) Watera (125:72:3) 
(2:2:1) 
Tryptophan .19 .52 .17 
N-Acetyltryptophan .43 .90 .36 ·58 .04 
N-Mathyltryptophan .32 .65 .46 
Indole Lactic Acid .36 .85 .25 .44 .04 
Indole Proprionic Acid .48 .93 .90 
Indole Acrylic Acid .36 .94 .84 
Indole Glycollic Acid .33 .88 .31 
Tryptamine .83c .72c 
N-Methyltryptamine .88c .73c 
N,N-Dimethyltryptamine .92c .74° 
1-' 
Indole Acetic Acid ·35 .92 ·19 .80 .46 0 \J1 
Indole Ace~ide .aoc .88c 
TAELE 36 continued 
Compound Rr 
Iso-Propanol N-Butanol Benzene Benzene Benzene 
Ammonia Acetic Acid Proprionic Acetic Acid Formic Acid 
Water Water Acid Waterb (80:1) 
{20:1:2) (12:3:5) Watera (125:72:3) 
(2:2:1) 
Indole Acetyl Glut~c Acid .o4 .84 .28 
Indole Acetyl Glutamine .27 
·75 .28 
Indole Acetyl Glycine .42 .85 
Indole Carboxylic Acid .27 
-92 .83 
Indole .90c .95c .94d 
Indoxyl Sulfate .6oc .46C 
Skatole .92c .98c .98d 
5-Hydro.xytryptophan .09 .29 .Old 
Serotonin .62 
·55 
N-Acetylserotonin .90 .86 
Bufotenin (as HCl) .98 .41 
5-Hydroxy Indole Acetic Acid .17 .80 .14d .ll 
.... 
.14 ·52 b\ Kynurenine 
Table 36 continued 
Co_ml'Q_un<l._ __ _ __ __ _ _ _ _ _ R.,. 
N-Acetylkynurenine 
3-Hydroxykynurenine 
:rcynurenio Acid 
Xanthurenic Acid 
Anthranilic Acid 
N-Acetylanthranilic Acid 
3-Bydroxyantb.ranilic Acid 
5-HYdroxyanthranilic Acid 
Urea 
Iso-Propanol 
Ammonia 
Water 
(20:1:2) 
.25 
.06 
.34 
.04 
.36 
.67 
.20c 
.2lc 
.42c 
N-l3utanol 
Acetic Acid 
Water 
(12:3:5) 
.85 
.41 
.62 
.60 
.91 
·92 
.84c 
.6oc 
·50c 
Benzene 
Proprionic 
Acid 
Watera 
(2:2:1) 
Benzene 
Acetic Acid 
Waterb 
(125:72:3) 
Benzene 
Formic Acid 
(80:1) 
~f values very variable in this system, e.g. IAA ranged from .75 to .98, AcT from .34 to .78, 
ILA from .24 to .63. Possibly due to sligl:lt variation in temperature. 
bnf values very variable in this system, e.g. IAA ranged from ... 74 to .98, AcT from .38 to .95, 
and ILA from .32 to .83. Possibly due to sligl:lt variation in temperature. 
~f values taken from Jepson (65). 
~f values taken from Armstrong, et al. (6}. 
.... 
~ 
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TABLE 37 
COMMON NAMES CORRESPONDING TO COLOR NUMBERS (SEE 
SPECTRUM AND COLOR CHARTS, FOLLOWING P. 576, WE13&l'ElPS 
NEW INTERNATIONAL DICTIONARY, 2ND EDITION, UNABRIDGED, 1951) 
Color No. Color Name Color No. Color Name 
28 Rose 98 Mauvette 
29 Ruby 99 Dahlia 
30 Opera Pink 100 Pansy Violet 
33 Cardinal 102 Mallow Pink 
36 Tile Red 106 Cameo Pink 
40 Tan llO Light Gray 
41 Chestnut lll Median Gray 
53 Olive Brown 112 Dark Gray 
79 Email (Gray-Green) 117 Tanbark 
82 Italian Blue 119 Apricot 
85 Cobalt Blue 120 Hazel 
ff{ Persian Blue 122 Zinc Orange 
90 Lavendar Blue 123 Tan 
91 Wisteria Blue 125 Cadmium Orange 
92 French Blue 136 Deep Chrome Yellow 
94 Lilac 137 Lemon Yellow 
95 Hyacinth 142 Baby Blue 
96 Violet 
High Brilliance 
IIO. Light gray 
II3. Flesh 
II6. Unnamed 
II9. Apricot 
I22. Zinc orange 
CHART C 
Oranges, tans, attd browns 
Medium Brilliance 
III : Median gray 
II4. Slate gray 
II? . Tanbark, or Algerian 
I20. Hazel 
I23. Tan 
I2$. Cadmium orange, or marigold yellow 126. Mandarin orange 
127. Cerise 
131. Coral 
135. Persian orange 
I39· Grass green 
143· Cerulean blue 
14 7. Lavender 
151. Amethyst 
CHART D 
Other colors of common names 
128. Claret, or Bordeaux 
132 . Cherry 
I36. Deep chrome yellow 
140. Emerald green 
144. Sky blue 
148. Wisteria (violet) 
152. Heliotrope 
129. Carmine 
133. :Maroon 
I3 7. Lemon yellow 
I4I. Aquagreen 
I45· Royal blue 
I49· Royal purple 
Low Brilliance 
II2. Dark gray 
IIS. Unnamed 
II8. Auburn 
I2I. Cocoa 
124. Caledonian brown 
130. English vermilion 
I34· Terra cotta 
I38. Ivory yellow 
I42. Baby blue 
146. Navy blue 
rso. Orchid 
ALPHABETICAL LIST OF COLORS SHOWN IN THE COLOR CHARTS 
Acorn . 49 Flesh 2, II3 Orchid ISO 
Algerian II7 French blue 92 Oriental red I30 
Amethyst (violet) ISI Fluorite violet 6,97 Pansy violet . roo 
Apple green . 57 Geranium 14,32 Peach . 34 
Apricot 39, II9 Golden yellow 43 Peacock (blue) 83 
Aquagreen I4I Goy a 130 Persian blue . 87 
Auburn II8 Grass green 139 Persian orange I35 
Baby blue 142 Gray, Dark II2 Pink 23,27 
Blue turquoise 78 " , Light 22 , 110 Plum IOI 
Bordeaux. !28 " , Median . I3 , III Pyrethrum yellow 51 
Bottle green . 7I Hazel . !20 Raisin. 109 
Brunswick green, mid. 65 Heliotrope . . !52 Raw umber . 45 
Cadmium orange 26, !25 Henna . 18, 24, 37 Roman violet roo 
Calamine blue 8I Hollyhock . I9, I08 Rose 28 
Caledonian brown . . 124 Hyacinth 95 Royal blue 145 
Cameo pink. . I06 Italian blue 9, 82 Royal purple I49 
Canary (yellow) 8,47 Ivory (yellow). I38 Ruby 29 
Capucine . 8, 47 Jonquil yellow. 42 Salmon (pink) r6,35 
Cardinal (red) 5.33 J ouvence blue So Sapphire (blue) . 20,86 
Carmine I29 Khaki 44 Sea blue 76 
Cerise . . I27 Lavender 147 Serpentine green 52 
Cerulean blue . 143 Lavender blue 90 Shamrock (green) 15,64 
Cherry . 3. 132 Lemon chrome 46 Sienna brown 121 
Chestnut (brown) 41 Lemon (yellow) I37 Sky blue 144 
Chrome green, med. 62 Lilac. I, 94 Slate gray II4 
Chrome primrose so Magenta I , 104 Sulphate green 70 
Chrome yellow, deep . 136 Mallow (red) 107 Tan 40, I2J 
Chromium green 58 Mallow pink . 102 Tanbark . II7 
Chrysolite green 54 Mallow purple . 103 Teak brown . 121 
Chrysoprase green 63 Mandarin orange 12, 126 Tea rose 4, 31 
Citrine 48 Marigold yellow 125 T erra cotta 134 
Claret (red) 128 Marine green . 68 Terre-verte 73 
Cobalt blue ss Maroon . 133 Tile reel 36 
Cocoa . 121 Mauvette 98 Turquoise (Ll uc) 25,75 
Coral 131 Moss (green) 55 Turquoise green. 72 
Dahlia 99 Mulberry 17, 93 Ultramarine (blue). ? . 89 
Dresden blue 88 l\Iyrtle (green) 77 Variscite green . 66 
Duck green 74 Navy (blue) . 146 Vermilion, English 130 
Egyptian green . 67 Nile (green) ro, 6o Violet . g6 
Email. 79 Old olive 53 Wisteria bl uc 91 
Emerald 6r Olive brown 53 Wisteria (violet) 148 
Emerald green 140 Olive (green) 21 , 56 Yew green 59 
English vermilion 130 Opera pink 30 Zinc orange I2:Z 
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EXPLANATION OF THE COLOR CHARTS AND COMMON NAMES OF THE COLORS 
IF the color squares shown at random in Chart A be examined for the purpose of arranging them in some systematic order, it will be 
seen that the colors exhibit certain outstanding differences from each other. The majority have a hue (see this term) more or less re-
sembling some hue of the spectrum. This is true even of certain purples like r, 6, II, 17, and 19 which show resemblances to both ends 
of the spectrum. All of these colors are chromatic (see this term) and differ from colors 13 and 22 which have no hue and hence are 
achromatic or neutral. 
If the chromatic colors in Chart A are arranged with their hues in the order of the spectrum and then examined, it will be seen that 
they exhibit still further differences from each other. Some of them, as r, 2, 4, and 23, are light; others, as 5, 6, 7, and I 7, are dark, while 
still others, as I8 and 24, are intermediate in brilliance (see this term). Certain light colors may be described as very light; certain dark 
colors, as 6 and I 7, as very dark. . 
If we arrange a large number of chromatic colors with respect to the two attributes hue and brilliance, we obtain an arrangement like 
that shown in Chart B (colors 27 to I09). The colors in the first row (30, 34, 38, 42, 46, so) are very light; those in the last row (93, 97, 
IOI, ros, 109) are very dark. In addition to these very light and very dark colors, a light, a medium, and a dark color in each of 24 hues 
is shown. The order of the hues exhibited in the successive columns is that indicated in the article COLOR (which see). Every sixth 
column presents one of the psychologically primary hues ; that is, the column of colors beginning with 27 is red, that beginning with so is 
yellow, with 69 green, and with 87 blue. Halfway between the primaries, in the columns beginning respectively with the numbers 38, 6o, 
78, and 98, are the hues red-yellow, yellow-green, green-blue, and blue-red. Following red is yellowish-red (3o), following red-yellow is 
yellowish red-yellow (42), following yellow is greenish-yellow (54), and so on, as stated under COLOR. Preceding red-yellow is reddish 
red-yellow (34), preceding yellow is reddish-yellow (46) and so on. The six intervals between each pair of psychologically primary 
hues are so chosen as to be visually constant. Blank spaces are met in the very light and very dark rows, since in practice no colors of 
common names are met having corresponding hues and brilliances. 
In this arrangement (Chart B) it is seen that certain colors stand out more vividly than others and among the colors shown in ran-
dom order (Chart A) it is clearly seen that colors 3, 7, 9, I2, and I9 differ vividly from the grays (as I3 and 22), while others as 2 and IO 
bear considerable resemblance to one or another of them. The difference is a difference of saturation (see this term) which is the third 
attribute of colors. If we now consider all colors of a given hue, as red-yellow, we can arrange them with respect to the two last-named 
attributes, brilliance and saturation. Thus in Chart C, the colors IIO to 126 are arranged in three rows according to brilliance, light 
(IIo-I 2 s), medium (I II- I 26), and dark (II2 to I 24), with the appropriate neutral gray at the extreme left of each row, the color of highest 
saturation at the extreme right. Any colors having hues like those of each of the 24 shown in Chart B, which may be described as red, 
yellow, green, or blue, or as intermediates of these (see COLOR), can be arranged in a manner similar to those at C. 
In Chart C the colors shown are not exactly of one hue since it was desired to show standard colors of co=on names. Similarly in 
Chart B not all of the light colors are exactly of equal brilliance, and so on, and for each group of three or four colors in a column there 
are, for similar reasons, slight variations of hue. The arrangements are, however, approximately correct. 
A number of standardized colors of co=on names do not have brilliances even roughly like those of the columns shown, but fall be-
tween, or may be considered as near the" border lines"; coral (I3 r), for example, is in brilliance about halfway between tea rose (3 I) and 
geranium (32) . A number of such colors (I27-I52) are shown in Chart D. 
CHART A 
The names of the colors are as follows: 
r. Same as 94· 2. Same as IIJ . 
6. Same as 97· 
ro . Same as 60. 
14. Same as 32 . 
r8. Same as 37· 
22 . Same as no. 
26. Same as 125. 
Very High 
Brilliance 
30. Opera pink 
34. Peach 
38. Utma,med 
5· Same as 33· 
9 Same as 82. 
13. Same as nr. 
17 . Same as 93· 
2r. Same as 56. 
25 . Same as 75· 
42. Jonquil yellow 
46. Lemon chrome 
so. Chrome primrose 
High 
Brilliance 
27. Pink (average) 
31. Tea rose 
35· Salmon 
39· Apricot 
43· Golden ye!low 
4 7. Canary yellow 
sr. Pyrethrum yellow 
54· Chrysolite green 
57. Apple green 
6o. N ile green 
63. Chrysoprase green 
66. Variscite green 
69. Uttnamed 
72. Turquoise green 
7 5. Turquoise blue 
7S. Blue turquoise 
Sr. Calamine blue 
S4. U~tnamed 
S7. Persian blue 
90. Lavender blue 
94· Lilac 
9S . Mauvette 
102. Mallow pink 
ro6. Cameo pink 
CHART B 
Medi1tm 
Brilliance 
2S. Rose (average) 
32. Geranium 
36. Tile red 
40. Tan 
44· Khaki 
4S . Citrine 
52. Serpentine green 
55· Moss green 
58. Chromium green 
6r. Emerald 
64. Shamrock green 
67. Egyptian green 
70. Sulphate green 
73· Terre-verte 
76. Sea blue 
79· Email 
S2. Italian blue 
Ss. Cobalt blue 
SS. Dresden blue 
9r. Wisteria blue 
95· Hyacinth 
99· Dahlia 
103. Mallow purple 
107. Mallow 
3· Same as 132. 
7. Same as 89. 
I r. Same as 104. 
15 . Same as 64. 
19. Same as roS. 
23. Sameas27. 
Low 
Brilliance 
29. R uby 
33. Cardinal 
37· Henna 
41. Chestnut 
45 · Raw umber 
49· Acorn 
53· Olive brown 
56. Olive green 
59· Yew green 
4· Same as 31. 
8. Same as 47· 
12 . Same as 126. 
r6. Same as 35 · 
20. Same as S6. 
24. Same as 37· 
Very Low 
Brilliance 
93 · Mulberry 
97. Fluorite violet 
ror. Plum 
ros. Unnamed 
109. Raisin 
62. Medium chrome green 
65. Medium Brunswick green 
68. Marine green 
7I. Bottle green 
74· Duck green 
77. Myrtle green 
So. J ouvence blue 
83. Peacock blue 
86. Sapphire blue 
89. Ultramarine 
92. French blue 
¢. Violet (average} 
roo. Pansy violet 
104 . Magenta 
ro8. Hollyhock 
SPECTRUM AND COLOR CHARTS 
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THE METABOLISM OF TRYP!'OPHAN IN RATS AND lN MAN 
Iris Miroy Ovshinsky 
ABSTRACT 
TryptoPhan and its metabolites have been implicated in various 
mental disorders including schizopnrenia. This serious disease of unknown 
etiology has become an increasingly important subject of biochemical 
investigation. In order to understand more fully the metabolism of 
tryptopnan in schizophrenia, an investigation of urinary metabolites 
was undertaken, utilizing radioactivity as a marker . 
Bats were studied to perfect the techniques and to provide 
possible indications of the metabolites to be looked for in man. Trypto-
Phan was administered to humans orally, to duplicate the normal route 
of intake, and intravenously, to obtain indications of tissue activity 
without the tryptopnan having been acted on by intestinal bacteria. 
The techniques employed were a combination of two-dimensional 
ascending paper chromatography and radioautography. The latter was 
useful in the visual identification of the urinary metabolites of radio-
active cl4_labelled tryptophan. Through the use of extraction procedures 
with various solvents, selective separation and identification were made 
possible. Concentration of the extracts provided for the detection of 
substances present in only minute quantities. 
Upon administration of D ,L-Tryptophan-j -c14 to rats and to ma.n, 
the following results were obtained : the mean percent recovery of radio-
activity in the rats was 4.4~ . Of the forty radioactive spots found in 
the radioautograms, eight were tentatively identified as: acetyltryptophan, 
5-hydroxyindoleacetic acid, 6-hydroxyskatole sulfate, indoleacetic acid, 
indoleacetylglycine, indolecarboxylic acid, kynurenic acid, and xanthurenic 
acid. Some unmetabolized tryptophan was also excreted. 
In the schizophrenic patients who received the tryptophan orally, 
there was a mean percent recovery of radioactivity of 32%. In those who 
received the tryptophan intravenously, the recovery lTas 43%· The rad.io-
autograms of human urines showed the presence of only one spot, tryptophan, 
probably the D form which is poorly metabolized in man. A normal control 
showed no difference from schizophrenic patients in recovery of radio-
activity or in the rad.ioautograms. 
Isopropyl ether extracts of one of the human urines showed the 
presence of 1-~ of the original radioactivity. Radioautograms of the 
extracts showed the presence of labelled acetyltryptophan, indoleacetic 
acid, indolelactic acid and two unknown metabolites. A chloroform 
extract of some of the human urines selectively extracted the indoleacetic 
acid. This was shown to be radioactive and both chromatographic and 
colorimetric evidence was obtained of its purity and identity. 
To further establish the metabolic patterns of tryptophan in 
schizophrenia, methods must be developed to identify the fragments of 
tryptophan which are incorporated in the body proteins and then slowly 
excreted at levels too low to be detected by current methods. It is 
hoped that labelled L-tryptophan will become available so that the 
metabolism of tryptophan in both normal persons and schizophrenic 
patients can be further delineated. 
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